Cloning, Expression and Structural Characterization of Human Metapneumovirus Fusion Glycoprotein by Cseke, Gabriella
CLONING, EXPRESSION AND STRUCTURAL CHARACTERIZATION OF 
HUMAN METAPNEUMOVIRUS FUSION GLYCOPROTEIN 
 
By 
 
Gabriella Cseke 
 
Dissertation 
Submitted to the Faculty of the 
 Graduate School of Vanderbilt University 
in partial fulfillment of the requirements for 
the degree of  
 
DOCTOR OF PHILOSOPHY  
in 
Chemistry 
 
December, 2006 
 
Nashville, Tennessee 
 
 
Approved: 
 
Professor David W. Wright 
Professor David E. Cliffel 
Professor James E. Crowe 
Professor Michael P. Stone 
Professor John V. Williams 
ACKNOWLEDGEMENTS 
 
When I came to Vanderbilt to start my graduate studies in chemistry I had no idea 
what my research project would be. I wanted to do chemistry combined with molecular 
biology and I was looking for an advisor, who had similar research interests, so I asked 
Dr. David Wright if I could join his group. He accepted me without question and gave me 
an opportunity in a new project to do hMPV research in collaboration with Dr. Crowe 
and Dr. John Williams. I hope he did not regret his decision, because it turned out to be a 
great one (at least for me). He gave me the freedom to do my research in a way as I 
wanted, but always reminded me for my responsibilities (meetings, exams, course work, 
etc.). Although I didn’t spend too much time doing my actual research in Dr. Wright’s 
lab, I want to thank the Wright lab members for their help, especially Scott (now Dr. 
Miller) for his peptides and for his help with my presentations along with Elizabeth 
(Liddy). Clare (now Dr. Clare Kenny-Carney) and Alex, who helped me with the 
proteomics studies, and Sarah and Malgorzata, who helped me to locate or find Dr. 
Wright or Scott whenever I needed help. 
I started my actual research in Dr. James Crowe’s lab. The six months I spent 
there probably finalized my decision to do science, or at least try to do it in the way as the 
“Crowe lab” does. First, I want to thank Dr. Crowe for his help in my research, my 
committee meetings and lab meeting presentations, and of course Fran House, who is the 
soul of the Crowe lab and of course the “Lab-Mom”. Many thanks to the past and present 
Crowe lab members: Nicole, Sean, Amber, Tom, Cuixia, Josh, Mike (Rock), Sandy, 
Mike (Lindquist), Chris, Sunny, Sujin, Sam, Emily, Kelly, Jungyun, Pat, Dr. Yu, Keipp 
 ii
and Bryan. Here I also want to say thanks to Melissa from Dr. Dermody’s lab, Dr. Jim 
Higginbotham and Dr. Kevin Weller for their help with flow cytometry, Dr. Amy Ham 
for her help with the disulfide-mapping and of course, Dr. Stone and Dr. Cliffel at the 
Chemistry Department, who gave me good advices on my committee meetings and 
qualifying exam. 
After the six months in the Crowe lab I continued my research in Dr. John 
Williams’s lab. Working in his group was the best experience that I had at Vanderbilt. 
John is an awesome mentor and a great person. I couldn’t wish for a better one. He taught 
me everything, from the basic lab techniques (his famous ‘sloppy’ pipetting) to how to 
give presentations and how to work together with other labs. No matter what, John was 
always there to help me and answer my questions. He supported me for three and a half 
years continuously; thanks John, very much! And of course, Sharon Tollefson. What can 
I say? Sharon is the nicest, kindest person I have ever met. She works hard, she never 
raises her voice, but helps you whenever, wherever and whatever you need help in. I also 
want to say thanks to the Williams lab members: Amy, Rohith, Alex, Sarah and Kathryn. 
And finally, I want to thank my family. Although they were far away, they 
supported me from home. My Grandma, who prayed for me, my Mom, who set an 
example how to be a good researcher, my Dad, who is a hard worker, a great teacher and 
the best Dad in the world, and my sister, Mariann, who is a fantastic sister. I couldn’t do 
this without you. 
And of course, more than anything, Tamas. He was there for me every day, all 
day, with his support and help. He was one reason, why I started my studies at 
Vanderbilt, and he was the one, why I could finish it. Thanks! 
 iii
TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS................................................................................................ ii 
LIST OF TABLES............................................................................................................ vii 
LIST OF FIGURES ......................................................................................................... viii 
LIST OF ABBREVIATIONS............................................................................................ ix 
 
Chapter 
I. INTRODUCTION........................................................................................................... 1 
 
1.1. Overview.................................................................................................................. 1 
1.2. Paramyxoviruses ...................................................................................................... 3 
Classification............................................................................................................... 3 
Genome organization, virion structure and viral proteins .......................................... 5 
Viral replication ........................................................................................................ 11 
1.3. Human Metapneumovirus...................................................................................... 13 
Classification............................................................................................................. 13 
Genome organization, viral proteins......................................................................... 14 
Clinical manifestation and epidemiology ................................................................. 17 
1.4. Fusion glycoprotein ............................................................................................... 19 
Fusion process........................................................................................................... 19 
F protein structure ..................................................................................................... 22 
 
II. CLONING, EXPRESSION AND PURIFICATION OF HUMAN 
METAPNEUMOVIRUS FUSION GLYCOPROTEIN............................................... 38 
 
2.1. Introduction............................................................................................................ 38 
2.2. Materials and Methods........................................................................................... 43 
Vaccinia virus expression system ............................................................................. 43 
Protein expression with pTracer vector .................................................................... 45 
F expression with pcDNA3.1/myc-His vector.......................................................... 47 
2.3. Results.................................................................................................................... 50 
2.4. Discussion .............................................................................................................. 56 
 
 iv
III. STRUCTURAL CHARACTERIZATION OF HMPV FUSION PROTEIN............. 59 
 
3.1. Introduction............................................................................................................ 59 
3.2. Circular dichroism spectroscopy, surface plasmon resonance .............................. 61 
3.3. N-glycosylation, site-directed mutagenesis ........................................................... 68 
3.4. Disulfide-mapping, computer models.................................................................... 75 
3.5. Discussion .............................................................................................................. 82 
 
IV. F PROTEIN BINDING TO RGD-SPECIFIC ADHESION MOLECULES.............. 85 
 
4.1. Introduction............................................................................................................ 85 
4.2. Materials and Methods........................................................................................... 88 
4.3. Results.................................................................................................................... 91 
4.4. Discussion ............................................................................................................ 103 
 
V. ANIMAL MODEL AND VACCINE DEVELOPMENT ......................................... 105 
 
5.1. Introduction.......................................................................................................... 105 
5.2. Materials and Methods......................................................................................... 107 
5.3. Results.................................................................................................................. 109 
5.4. Discussion ............................................................................................................ 113 
 
VI. CONCLUSION......................................................................................................... 116 
 
Future work................................................................................................................. 118 
 
REFERENCES ............................................................................................................... 119 
 
Appendix 
A. FPLC PURIFICATION OF HMPV F ECTODOMAIN USING HISTRAP COLUMN 
AND ÄKTA-FPLC SYSTEM.................................................................................... 125 
B. SPR-BIACORE ANALYSIS OF HMPV F BINDING TO HMPV-SPECIFIC 
HUMAN MONOCLONAL ANTIBODY.................................................................. 128 
 v
LIST OF TABLES 
 
Table Page 
 
1. Classification of Paramyxoviridae virus family ............................................................. 4 
 
2. PCR primers designed to generate N-glycosylation mutants. ...................................... 70 
 
3. Histopathological scoring of lung sections from immunized groups of cotton rats after 
hMPV challenge.. ....................................................................................................... 113 
 
4. Parameters for purification protocol of hMPV F ectodomain using ÄKTA-FPLC 
system and 5 ml HisTrap column............................................................................... 127 
 
 vi
LIST OF FIGURES 
 
Figure Page 
 
1. Genomic maps of the Paramyxoviridae virus family members...................................... 6 
 
2. 3D structure of Pneumovirus.. ........................................................................................ 7 
 
3. Schematic picture of membrane fusion......................................................................... 20 
 
4. Fusion model for influenza virus .................................................................................. 21 
 
5. The conformations of influenza hemagglutinin. ........................................................... 23 
 
6. Spring-loaded conformational change of influenza HA2. ............................................ 24 
 
7. Model for membrane deformation catalyzed by influenza HA .................................... 25 
 
8. Diagrams of the N36/C34 complex. ............................................................................. 27 
 
9. Schematic diagram of RSV F protein. .......................................................................... 29 
 
10. Top and side views of SV5 F1 core trimer compared to other type I glycoproteins .. 31 
 
11. Space-filling model of NDV F trimer. ........................................................................ 32 
 
12. Structure of the hPIV 3 F ectodomain. ....................................................................... 34 
 
13. Pre- and post-fusion F protein conformations. ........................................................... 36 
 
14. Model for F-mediated membrane fusion. ................................................................... 37 
 
15. Regulation of target gene expression in the absence (-) or presence (+) of inducer... 40 
 
16. Schematic diagram of pTracer-EF/V5-His mammalian expression vector. ............... 42 
 
17. Schematic diagram of pcDNA3.1/myc-His expression vector. .................................. 43 
 
18. HMPV F∆TM expression in LLC-MK2 cells using pTracer expression vector. ....... 52 
 
19 Purified FΔTM under denaturing, non-reducing conditions........................................ 54 
 
 vii
20. Purified FΔTM under native conditions. .................................................................... 55 
 
21. FΔTM under denaturing conditions. ........................................................................... 55 
 
22. CD spectrum of hMPV F ectodomain shows predominant α-helical secondary 
structure....................................................................................................................... 65 
 
23. SPR-BIAcore kinetic analysis of anti-hMPV human monoclonal Fab binding to 
hMPV F ectodomain. .................................................................................................. 67 
 
24. Western blot of hMPV FΔTM digested with N-glycosidase F................................... 72 
 
25. Western blots of FΔTM and mutated proteins............................................................ 75 
 
26. Coverage map of FΔTM digested with trypsin and chymotrypsin. ............................ 80 
 
27. Hexameric fusion core of hMPV F model. ................................................................ 81 
 
28. Effect of decreasing EDTA concentration on infectivity of hMPV and RSV............ 92 
 
29. Effect of decreasing GRGDSP linear peptide concentration on hMPV and RSV 
infectivity. ................................................................................................................... 93 
 
30. Effect of integrin-function blocking antibodies on hMPV and RSV infectivity. ....... 95 
 
31. Histograms of flow cytometric analysis of LLC-MK2 cells stained for cell surface 
binding of hMPV F protein......................................................................................... 97 
 
32. Flow cytometric analysis of siRNA transfected LLC-MK2 cells............................... 98 
 
33. Infectivity of LLC-MK2 cells transfected with siRNA for αV and/or β1 integrins. .. 99 
 
34. Histograms of flow cytometric analysis of integrin surface expression in transiently 
transfected CHO cells. .............................................................................................. 101 
 
35. Effect of integrin function-blocking antibodies on infectivity of hMPV in integrin-
transfected CHO cells. .............................................................................................. 102 
 
36. Nasal and lung hMPV titer and reciprocal serum antibody titer in cotton rats......... 112 
 
37. Representative sections demonstrating histopathology of hMPV infection in lungs of 
immunized cotton rats............................................................................................... 115 
 
38. Kinetic analysis of hMPV F binding to anti-HMPV human monoclonal Fab.......... 129 
 
 viii
LIST OF ABBREVIATIONS 
 
 
Amino acids (IUPAC, 1968): 
Alanine A (Ala) 
Arginine R (Arg) 
Asparagine N (Asn) 
Aspartic acid D (Asp) 
Cysteine C (Cys) 
Glutamic acid E (Glu) 
Glutamine Q (Gln) 
Glycine G (Gly) 
Histidine H (His) 
Isoleucine I (Ile) 
Leucine L (Leu) 
Lysine K (Lys) 
Methionine M (Met) 
Phenylalanine F (Phe) 
Proline P (Pro) 
Serine S (Ser) 
Threonine T (Thr) 
Tryptophane W (Trp) 
Tyrosine Y (Tyr) 
Valine V (Val) 
 
BLAST Basic Local Alignment Search Tool 
BSA bovine serum albumin 
°C degrees Celsius 
CD circular dichroism 
cDNA complementary DNA 
E.coli Escherichia coli 
EDTA ethylenediaminetetraaceticacid 
ELISA enzyme-linked immunosorbent assay 
FBS fetal bovine serum 
FP fusion peptide 
F protein fusion protein 
G protein attachment protein 
h hour 
HA hemagglutinin 
 ix
hMPV human metapneumovirus 
HN hemagglutinin-neuraminidase 
HR heptad repeat 
hPIV human parainfluenza virus 
kDa kilo Dalton 
kb kilobase 
mg milligram 
µg microgram 
ml milliliter 
µl microliter 
MW molecular weight 
MWCO molecular weight cut off 
NDV Newcastle disease virus 
nm nanometer 
nt nucleotide 
OD optical density 
ORF open reading frame 
PBS phosphate buffered saline 
PBS-T phosphate buffered saline with Tween 20 
PCR polymerase chain reaction 
PNGase F N-glycosidase F 
RdRp RNA-dependent RNA polymerase 
rpm revolutions per minute 
 x
RSV respiratory syncytial virus 
RT room temperature 
RT-PCR reverse transcriptase-polymerase chain reaction 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
TBS-T Tris-buffered saline with Tween-20 
TM transmembrane 
U unit 
V Volt 
 
 xi
CHAPTER I 
 
INTRODUCTION 
 
1.1. Overview 
Human metapneumovirus (hMPV) is a recently discovered Paramyxovirus, which 
causes upper and lower respiratory tract infection in infants, young children, elderly and 
immunocompromized patients worldwide. This thesis concentrates on the structural 
characterization of the human metapneumovirus fusion (F) glycoprotein. 
In Chapter I we show the taxonomy of the Paramyxoviridae virus family, list a 
couple of important viruses, which are human, mammalian, bird or rodent pathogens, and 
briefly overview the genome organization, virion structure and replication mechanism of 
Paramyxoviruses. In the following section we characterize the human metapneumovirus, 
specifically highlighting the similarities with other family members and showing details 
about the viral genome, structure and clinical manifestation of the infection. At the end of 
this chapter we describe the structural and functional characteristics of Paramyxovirus 
fusion proteins, their role in enveloped virus entry into the host cell, the important 
domains and structural units of the protein and the conformation change in the secondary 
and tertiary structure, which plays a key role in the viral entry process and membrane 
fusion. 
In Chapter II we provide the theoretical background, experimental setups, 
materials, methods and results of cloning, expression and purification of hMPV F 
ectodomain. In this chapter we describe several different methods that we have tried to 
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express the fusion glycoprotein. The most successful method with pcDNA3.1 vector 
system is fully detailed at the end of this chapter. All of the procedures and steps were 
developed and optimized specifically for hMPV F protein expression and purification. 
Chapter III contains the structural and biochemical characterization of hMPV F 
protein. We used several different techniques to determine the protein’s secondary and 
tertiary structure. Besides the results of gel electrophoresis, IMAC chromatography and 
circular dichroism spectroscopy and SPR measurements we give a detailed description of 
the N-glycosylation/site-directed mutagenesis experiments and disulfide mapping of 
hMPV F protein. 
In Chapter IV we will illustrate important biological features of the F protein. A 
group of specific cellular receptors called integrins bind proteins that contain RGD (Arg-
Gly-Asp) motifs. We show that hMPV F protein, which contains the RGD sequence in 
the F1 subunit, binds to certain integrins and this binding can be inhibited by several 
ways. This fact might be a crucial point in the understanding of virus attachment and 
binding to host cells and the entry process. 
Our hMPV F construct is a valuable vaccine candidate and the cotton rat is a good 
animal model for hMPV infection and vaccine studies. We showed that the hMPV F 
ectodomain is immunogenic and protective in cotton rats. Chapter V contains the detailed 
description and results of our vaccine development experiments. 
Finally in Chapter VI we give a short discussion and conclusion of our results and 
future directions regarding further structural studies of hMPV F. 
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1.2. Paramyxoviruses 
Classification 
The Paramyxoviridae virus family contains many important human and animal 
pathogens. Some of them are the most infectious human pathogens (measles), some of 
them have major economic impact on poultry (Avian pneumovirus, Newcastle disease 
virus) and animal rearing (rinderpest virus, bovine respiratory virus), and there are a 
couple of newly discovered viruses also in this group (Human metapneumovirus, Hendra 
and Nipah viruses). The Paramyxoviruses are enveloped, negative-sense, single-stranded 
RNA viruses. The virus family has been reclassified in 2000 into two subfamilies: the 
Paramyxovirinae and the Pneumovirinae. The newest classification is based on the 
genomic organization, the virion structure, the biological role of the viral proteins and the 
sequence relationship of the encoded proteins1. Paramyxovirinae subfamily has five 
genera: Avulavirus, Henipavirus, Rubulavirus, Respirovirus and Morbillivirus, 
Pneumovirinae subfamily contains two genera: Pneumovirus and Metapneumovirus 
(Table 1)2. Pneumoviruses can be distinguished from the Paramyxovirinae 
morphologically because Pneumovirinae have narrower nucleocapsids and their 
attachment protein is very different from that of the Paramyxovirinae. However, all of the 
Paramyxoviruses have a protein (F), which mediates viral and host cell membrane fusion 
at neutral pH. This makes an important difference from the Orthomyxoviridae virus 
family, where the viral-cell membrane fusion occurs at low pH in endosomal 
compartments. 
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Table 1. Classification of Paramyxoviridae virus family 
Family: Paramyxoviridae 
Subfamily: Paramyxovirinae 
Genus: Avulavirus 
Newcastle disease virus (NDV) 
Genus: Henipavirus 
Hendra virus 
Nipah virus 
Genus: Respirovirus 
Sendai virus 
Human parainfluenza virus types 1 and 3 (hPIV 1 and 3) 
Bovine parainfluenza virus type 3 
Genus: Rubulavirus 
Mumps virus 
Simian parainfluenza virus type 5 
Human parainfluenza virus types 2 and 4 (hPIV 2 and 4) 
Genus: Morbillivirus 
Measles virus 
Dolphin morbillivirus 
Canine distemper virus 
Phocine distemper virus 
Rinderpest virus 
Subfamily: Pneumovirinae 
Genus: Pneumovirus 
Human respiratory syncytial virus (hRSV) 
Bovine respiratory syncytial virus (bRSV) 
Pneumonia virus of mice 
Genus: Metapneumovirus 
Human metapneumovirus (hMPV) 
Avian pneumovirus 
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Genome organization, virion structure and viral proteins 
The Paramyxovirus genome is a single strand of non-segmented RNA genome 
with negative polarity. It is 15 to 19 kb in length and contains six to ten tandemly linked 
genes (seven for some rubulaviruses and eight to ten in pneumoviruses)1, 2. The genome 
also contains an approximately 50 nucleotide long 3’ extracistronic leader region and a 
50 to 161 nt long 5’ trailer sequence, which are essential in the transcription and 
replication processes1 (Figure 1). 
The Paramyxovirus virion is generally irregular spherical and 150 to 350 nm in 
diameter, but pleiomorphic and filamentous forms can be observed too. The virion is 
surrounded by a lipid bilayer, which derives from the host cell plasma membrane during 
budding. In the lipid envelope two surface glycoproteins are inserted (F and G or HN or 
H) and they extend about 8-12 nm from the surface of the membrane. Inside the envelope 
is the nucleocapsid core, which contains the single negative-stranded RNA genome, the 
nucleocapsidprotein (N), the phosphoprotein (P) and the large (L) protein. Between the 
envelope and the nucleocapsid is the matrix (M) protein. This protein is very important in 
virion architecture. In addition to the structural genes Paramyxoviruses also contain 
“accessory’ genes, which are transcriptional units or their function is still unknown. 
Figure 2 shows the 3D structure of Pneumoviruses with the lipid membrane, the 
nucleocapsid, the matrix, fusion and attachment proteins. 
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Figure 1. Genomic maps of the Paramyxoviridae virus family members. Figure is 
adapted from Easton et al.2 
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The nucleocapsid (N) protein encapsidates the RNA genome and makes it 
resistant to RNases. It associates with the P and L proteins during the 
transcription/replication process and also interacts with the M protein. The intracellular 
concentration of the free nucleocapsid protein is important in replication, because it is 
thought to control the switch from transcription to viral replication. The N protein 
contains 390-553 amino acids with a molecular weight of 53,167 to 57,896. 
 
 
Figure 2. 3D structure of Pneumovirus. Adapted from Pneumovirus Laboratory, 
University of Warwick, UK. 
 
The P gene of the Paramyxovirinae subfamily contains several overlapping 
reading frames on a single mRNA transcript, but in the Pneumovirinae it encodes for the 
P or phosphoprotein, which is essential for viral RNA synthesis. The catalytic domain of 
the viral RNA-dependent RNA polymerase in the L protein binds to the N-RNA complex 
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via the P protein, so the carboxy terminus of the phosphoprotein represents the 
polymerase (pol) cofactor module. In hRSV the P protein is smaller than that of the 
Paramyxovirinae subfamily; it is 241 amino acids long and forms the major 
phosphorylated complex in the virion. 
The L or large protein is the viral RNA-dependent RNA polymerase; it is the 
largest protein in the virion. Its gene is at the most distal position from the promoter in 
the transcriptional map, so it is the last to be transcribed and the protein is less abundant. 
In hRSV a putative nucleotide-binding domain involved in capping mRNA was 
identified, which further suggests that the L protein contains polymerase motifs. 
The matrix (M) protein is the most abundant protein in Paramyxoviruses. An 
electron-dense layer under the lipid bilayer represents this protein in the virion. The M 
protein is non-glycosylated and based on the nucleotide sequence of the M gene in 
Paramyxoviruses this protein has a net basic charge and contains hydrophobic domains. It 
is also associated with the peripheral viral membranes. In genetically engineered 
recombinant measles virus and SV5 the M protein has a major role in particle assembly 
and budding. It is considered as the central organizer of viral morphogenesis for these 
viruses, since it is associated with the cytoplasmic tails of the surface glycoproteins, the 
nucleocapsid and the lipid bilayer. 
Paramyxoviruses encode for two integral glycoproteins: the attachment (HN, H or 
G) and the fusion (F) proteins, some rubulaviruses and pneumoviruses also have a third 
surface glycoprotein (SH). The attachment protein in respiroviruses and rubulaviruses 
binds to sialic acid-containing receptors on the cell surface. Because of the low affinity 
but high avidity of the binding, these viruses cause hemagglutination meaning they 
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agglutinate erythrocytes. The attachment protein of these paramyxoviruses also has 
neuraminidase activity (enzymatic cleavage of sialic acid from the surface of infected 
cells and virions), so the protein of respiro- and rubulaviruses is called hemagglutinin-
neuraminidase (HN). Besides the hemagglutinin and neuraminidase activity, in most 
paramyxoviruses HN protein also has fusion-promoting activity, since co-expression of F 
and HN protein is needed for successful virus-cell or cell-cell membrane fusion. The 
attachment protein of Morbilliviruses, like measles, binds to CD46 and CDw150/SLAM 
surface receptors and the protein causes hemagglutination but it has no neuraminidase or 
esterase activity, so it is designated as H protein. The attachment protein of 
Pneumoviruses, like hRSV or hMPV, does not have neuraminidase or hemagglutinating 
activity and it is called the G protein. In RSV G protein binds to heparan sulfate and G-
specific antibodies inhibit virus binding to cultured cells. The G protein is a type II 
glycoprotein and in Pneumoviruses it is heavily glycosylated (N-linked and O-linked 
glycosylation). Studies showed that recombinant RSV and hMPV strains that lack G 
protein were attenuated, but replicated efficiently in Vero cells and in hamsters, so G 
protein is not essential in vitro and in vivo. These findings also mean that the fusion (F) 
protein might have some binding activity too. 
The fusion (F) glycoprotein is a type I transmembrane protein, which mediates 
viral envelope and cell membrane fusion at neutral pH during viral entry and cell-cell 
membrane fusion during syncytia formation in infected cells. The F protein is synthesized 
as an inactive F0 precursor and cleaved into the disulfide-linked F1 and F2 subunits by 
host cell proteases. The protein assembles into homotrimers, the N-terminal hydrophobic 
fusion peptide in the F1 subunit inserts into the target membrane, and a conformational 
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change in the protein structure brings the viral and cellular membrane into close 
proximity resulting membrane fusion (for more details see 1.4.). SV5, measles or RSV F 
cDNAs expressed in mammalian cells induced syncytia formation without co-expression 
of the attachment protein, which means that F protein has some attachment activity. 
However, for many other paramyxoviruses, like hPIV-2, hPIV-3, NDV, CDV and mumps 
virus co-expression of the attachment protein is necessary for multinucleated syncytium 
formation. It is important to mention that F and G proteins induce neutralizing antibodies. 
In hRSV monoclonal antibodies raised against the RSV F protein neutralize infectivity 
and inhibit fusion. For some of them the antigenic epitopes are conformation-dependent, 
so in these cases monoclonal and polyclonal antibodies don’t react with denatured 
protein. By comparison, antibodies against G protein recognize denatured protein, 
indicating no structural dependence. Individual monoclonal antibodies raised against 
hRSV G protein don’t neutralize infectivity efficiently, although a mixture of MAbs give 
more complete neutralization. In hMPV, however, the F protein appears to be the only 
neutralizing and protective antigen and vectors expressing the G protein were poorly 
immunogenic and protective in rodents. 
Pneumoviruses, rubulaviruses, SV5 and mumps virus encode for a small 
hydrophobic protein (SH), which represents the third envelope protein in these viruses. 
The SH protein is a type II membrane glycoprotein and its function in the virus life cycle 
is still unknown. Deletion of the SH gene from recombinant RSV resulted no alterations 
in viral growth in vitro or in vivo, and it has also been found that the gene can be deleted 
spontaneously in viruses passaged extensively in vitro. 
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In pneumoviruses the M2 gene contains two overlapping open reading frames: 
M2-1 and M2-2. The translation of the M2-2 gene is not clear, but it involves a ribosomal 
stop-restart mechanism. In RSV the M2-1 protein is an essential transcriptional 
elongation factor and the non-essential M2-2 is thought to be involved in the transcription 
and RNA replication process. 
In RSV there are two non-structural proteins at the beginning of the genomic map 
designated as NS1 and NS2, which are missing from hMPV and other paramyxoviruses. 
The function of these proteins is still unknown, but they seem to be non-essential as 
deletion of NS1 and NS2 genes resulted viable viruses with a slower viral growth rate. 
 
Viral replication 
After viral adsorption to the host cell surface receptors the viral membrane fuses 
with the host cell plasma membrane at neutral pH and the viral nucleocapsid is released 
into the cytoplasm, where all steps of the paramyxovirus replication take place. A single 
growth cycle takes usually 14-30 hours in cell culture, but for some strains it can be as 
short as 10 hours1. Paramyxoviruses are single, linear negative-sense RNA viruses and 
the RNA genome is transcribed exclusively in the cytoplasm by viral RNA-dependent 
RNA polymerase (RdRp) and the primary viral transcription begins shortly after viral 
infection. The genomic RNA is tightly wrapped with N protein, which makes it resistant 
to RNases and this N-RNA complex serves as a template for RdRp, which would not 
recognize a viral RNA lacking the N protein. The viral polymerase functions in two 
distinct modes: transcription and replication. In the transcription mode, it copies the viral 
genome to produce mRNAs corresponding to each gene by a stop-restart mechanism3. 
 11
The transcription starts at the 3’ end to generate the (+) leader RNA and then the 5’-
capped and 3’-polyadenylated mRNAs by stopping and restarting at each junction. The 
transcription process exhibits polarity, which means that the genes most proximal to the 
promoter at the 3’ end are transcribed most abundantly. This is also reflected in the 
relative abundance of the corresponding viral proteins3, 4. The viral mRNA is translated to 
viral proteins by host cell translation machinery. Transcription and translation generate 
more N protein, which wraps the newly transcribed RNA, and also more L protein 
boosting the transcription further. Once the primary transcripts generated enough viral 
proteins transcription is switched to replication. During replication the RdRp ignores the 
intergenic stop signals at the junctions and synthesizes a full-length positive-sense 
(mRNA sense) complementary strand of the viral genome called the antigenome. The 
antigenome is also wrapped with N protein, no mRNAs are transcribed from it and serves 
as a template for genomic replication to produce more full-length negative-sense viral 
genome. 
At the end of the viral life cycle virus particles assemble by packaging the newly 
formed, encapsidated genome and viral proteins together, and the virion particles bud 
from the apical surface of the host cell in form of filament structures. It is thought that the 
accumulation of the M protein is the trigger to initiate the assembly of virions2. 
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1.3. Human Metapneumovirus 
Classification 
In 2001 van den Hoogen et al. in the Netherlands reported the isolation of human 
metapneumovirus (hMPV) from nasopharyngeal aspirate samples taken from young 
children5. The newly discovered virus showed a high percentage of sequence identity 
with avian pneumovirus (APV) serotype C, the avian pneumovirus primarily found in 
turkeys and chickens in the United States6. The overall percentage of amino acid 
sequence identity between APV and hMPV N, P, M, F, M2-1, M2-2 and L ORFs was 56 
to 88%7. Until the discovery of hMPV, APV was the sole member of the 
Metapneumovirus genus in the Pneumovirinae subfamily of the Paramyxoviridae virus 
family. But because of the similar genomic organization, the high percentage of sequence 
identity and the evidence provided by phylogenetic analyses the human metapneumovirus 
became the first mammalian member of the Metapneumovirus genus. The Pneumovirinae 
subfamily also contains the Pneumovirus genus with important mammalian respiratory 
pathogens (human, ovine, bovine RSV). 
The sequence variations between different virus isolates of hMPV in the N, M, F 
and L genes revealed the existence of two different genotypes, genotype A and B. Based 
on further small differences in the sequences each of the two major subgroups has 2 
minor groups: A1, A2, B1 and B2. 
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Genome organization, viral proteins 
 
The hMPV genome is a single strand of negative-sense RNA that ranges in length 
from 13,280 to 13,335 nucleotides (nt) for the available sequences. The genome contains 
eight genes and encodes for nine proteins7, 8. The gene constellations of pneumoviruses 
and metapneumoviruses are different; metapneumoviruses lack the non-structural 
proteins NS1 and NS2. Comparing the genomic organization of human respiratory 
syncytial virus (3’-NS1-NS2-N-P-M-SH-G-F-M2-L-5’) and hMPV (3’-N-P-M-F-M2-
SH-G-L-5’) we can see a difference not only in the numbers of the encoded proteins but 
in the relative positions of F, G and SH proteins2. By analogy to the hRSV the hMPV 
proteins are the following: N, nucleoprotein; P, phosphoprotein; M, matrix protein; F, 
fusion glycoprotein; M2-1, putative transcription factor; M2-2, RNA synthesis regulatory 
factor; SH, small hydrophobic protein of unknown function; G, attachment glycoprotein 
and L, viral polymerase. 
The first gene in the genomic map of hMPV encodes for the 394 amino acid long 
nucleoprotein (N). Its length is identical to the N protein of APV-C and shows 88% 
sequence identity with it7. This is the most abundant protein translated from mRNA. The 
N protein binds the entire length of the viral genomic and antigenomic RNA. 
The second open reading frame in the genomic map is the phosphoprotein (P). Its 
length is 294 aa and it shares 66% sequence identity with APV-C P protein, but only 22% 
with the P protein of RSV. The phosphoprotein is associated with the nucleocapsid and 
also serves as a polymerase cofactor. In Paramyxoviruses it forms a soluble complex with 
the free monomeric N protein. 
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The matrix (M) protein is the third in the hMPV genomic map; it is 254 aa long. It 
builds up the inner surface of the viral envelope and it is very important in virion 
morphogenesis. The sequence identity with APV-C M is 76-87%, and with RSV M it is 
37-38%. 
The position of the gene encoding for the fusion (F) protein is right after the M 
gene in metapneumoviruses, in RSV it is after the SH and G genes, The hMPV F protein 
is 539 aa long, sequence analysis revealed 67% sequence identity with APV-C fusion 
protein and only 10-18% with other pneumovirus F proteins. The fusion glycoprotein is a 
type I transmembrane surface protein with important role in viral penetration and 
syncytium formation. It is synthesized as F0 precursor, which will be cleaved into the 
fusion active F1 and F2 subunits by host cell proteases. The three N-linked glycosylation 
sites present in the F of hMPV are conserved in all of the isolates worldwide, but none of 
these sites are shared with RSV. However, some of the 14 cysteine residues (12 in F1 and 
2 in F2) are conserved among all paramyxoviruses. 
The M2 gene is unique to the members of the Pneumovirinae subfamily. Two 
ORFs have been observed in all pneumoviruses. The first ORF represents the M2-1 
protein, which enhances the processivity of the viral polymerase and it is called putative 
transcription factor. This protein is 187 aa long and it shows the highest sequence identity 
to the APV-C M2-1 protein. Its N-terminal half has 100% identity with APV-C in the 
first 80 aa residues of the protein.  
The second ORF (M2-2) overlaps with the M2-1 ORF in all pneumoviruses. The 
M2-2 protein is thought to be involved in the control of the switch between virus RNA 
replication and transcription and it is called the RNA synthesis regulatory factor. This 
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protein doesn’t show as high similarity to APV or RSV proteins as M2-1. Sequence 
comparison revealed only 56% sequence identity between hMPV and APV-C M2-2. 
The gene of small hydrophobic protein (SH) encodes for a 183 aa long protein 
and it is located next to the M2 ORF. The amino acid composition of SH is relatively 
similar to that of APV and RSV, but the numbers of cysteine residues and N-
glycosylation sites are different in case of APV and RSV. The SH protein is 
transmembrane surface glycoprotein with N-linked sugars and polylactosaminoglycans. 
Its function is unknown and deletion of the SH gene results viable but slightly attenuated 
viruses in case of RSV. 
The gene of the major attachment (G) glycoprotein encodes for a heavily N- and 
O-glycosylated, 236 aa long protein. Basic Local Alignment Search Tool (BLAST) 
analyses revealed no discernible sequence identity at the nucleotide or amino acid 
sequence level with other known virus genes or gene products. Low percentage sequence 
identity found with other G proteins, such as those of APV-A and B (38%) and RSV-A 
and B (53%). In RSV deletion of the gene results viable but attenuated virus. 
The last open reading frame of the hMPV genome is the gene of the RNA-
dependent RNA polymerase component of the replication and transcription complexes. 
The L gene encodes for a 2005 aa protein, which shares 64% sequence identity with 
APV-A, 44% with RSV and 13-15% with other paramyxoviruses L proteins. The L 
protein contains the catalytic domains of the RNA dependent RNA polymerase and it is 
associated with the nucleocapsid. 
The non-coding regions between the ORFs of pneumoviruses contain gene end 
signals, intergenic regions and gene start signals and they vary in size and sequence. The 
 16
non-coding regions between the hMPV ORFs range in size from 23 to 209 nt and don’t 
show significant sequence similarity with APV or RSV. 
 
Clinical manifestation and epidemiology 
The clinical symptoms of hMPV are similar to the respiratory illnesses caused by 
human respiratory syncytial virus, which can range from mild respiratory problems to 
more severe illnesses. The clinical manifestations of hMPV infection in young children 
include bronchiolitis, croup, pneumonia, wheezing and asthma exacerbations. In infants 
hMPV is also associated with a substantial number of upper respiratory infections (URI) 
and with acute otitis media (AOM)9. The incidence of hMPV-associated lower 
respiratory infections (LRI) in young children is in the range from 5 to 15%, and it varies 
with geographical locations and time of the year. In older children and in adults, 
especially in the elderly hMPV causes upper respiratory tract infection, croup, laryngitis, 
bronchitis, asthma exacerbation and pneumonia. The peak age of hospitalization with 
hMPV occurs during 6 to 12 months of age. By the age of 5 most of the people appear to 
experience primary hMPV infection and reinfection is common5, 10. 
At Vanderbilt University Medical Center Williams et al.10 tested nasal wash 
specimens for human metapneumovirus obtained from otherwise healthy children 
presenting with acute respiratory tract illness. The Vanderbilt Vaccine Clinic in Nashville 
followed 2009 infants and children over a 25-year period from 1976 to 2001 and in 249 
children with lower respiratory tract infection no virus was identified previously. In this 
study they found that 20% of the specimens from children with lower respiratory tract 
illness contained human metapneumovirus RNA by RT-PCR or viable virus by the 
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presence of CPE in cell cultures. These samples were previously determined as virus-
negative samples for all other respiratory viruses. By looking at all of the lower 
respiratory tract infections, 12% were due to hMPV in this cohort. It was also found that 
15% of upper respiratory tract infections were caused by human metapneumovirus. The 
mean age of children with hMPV was 11.6 months and 78% of the human 
metapneumovirus infections occurred between December and April. 
The hMPV season overlaps with those of RSV and influenza virus. HMPV 
infections occur during the late winter and early spring months, but the peak incidence of 
hMPV is usually one or two month later than the peak of RSV. Because the seasonal 
distribution of hMPV and RSV overlap, the potential for dual infection exists. Several 
studies found a coinfection rate of <10 %, but one report from the United Kingdom 
showed that 70% of the RSV-infected children, who required intensive care in Liverpool, 
were coinfected with hMPV8.  
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1.4. Fusion glycoprotein 
Fusion process 
Membrane fusion is necessary for a large number of diverse biological processes 
for instance protein trafficking, endo- and exocytosis, protein secretion, synaptic 
transmissions, fertilization, myoblast fusion and viral infections. Without the specific 
proteins that mediate membrane fusion, formation of a single lipid bilayer from distinct 
membranes would be very slow. When two juxtaposed membrane begin to fuse the 
contacting monolayers (called ‘cis’ leaflets) have merged, but the distal layers (the ‘trans’ 
leaflets) remain intact. This formation is often referred as the ‘stalk’. The hemifusion 
intermediate results from the juxtaposition of the trans monolayers, which evolves to the 
fusion pore, the next intermediate that allows mixing of the aqueous content of the fusing 
membranes. The schematic picture of membrane fusion is shown in Figure 311. Infection 
of eukaryotic cells by enveloped viruses requires the fusion of the viral and the plasma or 
endosomal membranes. In case of influenza virus, which belongs to the 
Orthomyxoviridae virus family, the viral entry and membrane fusion is a pH-dependent 
process. Fusion of the endosomal and plasma membrane requires low pH (pH = 5) 12, 13. 
The membrane fusion process directed by Paramyxovirus glycoproteins is of 
particular interest, because it is pH-independent and because it requires two separately 
synthesized glycoproteins, the attachment (G, H or HN) and the fusion (F) 
glycoproteins14. Paramyxoviruses initiate infection by attaching to cell surface receptors 
allowing fusion of the viral membrane with the host cell plasma membrane. Surface 
receptors have been identified for a number of paramyxoviruses, for example SV5 binds 
to sialic acid, RSV to heparan sulfate, Hendra and Nipah virus G proteins bind to Ephrin 
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B2 and for measles CD46 and CDw150/SLAM were identified as cellular surface 
receptors15. 
 
Figure 3. Schematic picture of membrane fusion. A) Intermediate steps from intact 
membranes to fusion pore formation. B) Packing voids, the space left between cis and 
trans monolayers are filled by phospholipid chains. Adapted from Blumenthal et al.11 
 
Membrane fusion generally proceeds in a series of specific steps: (1) viral 
attachment to the surface of the host cell, (2) F protein activation and conformational 
change, (3) approach of the viral and host cell membranes, (4) pore formation, (5) pore 
expansion and (6) membrane fusion (Figure 4)11, 13. The current accepted hypothesis 
postulates that, at one stage of the fusion process, the viral fusion proteins interact 
simultaneously with both the viral and cell membranes, therefore bridging the gap 
between them12. The paramyxovirus fusion is pH-independent, meaning the infection 
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does not require the acidic pH of the endosomes, so it can occur at the plasma 
membranes. As a result of the acid independence infected cells expressing the viral 
attachment and fusion glycoproteins can fuse with the adjacent cells resulting in syncytia 
(giant cell with multiple nuclei) formation, a hallmark of paramyxovirus infection14. 
 
 
Figure 4. Fusion model for influenza virus13 
 
The detailed thermodynamic analysis of influenza hemagglutinin binding to the 
lipid bilayer was published by Li et al. 16. The interaction of the fusion peptides with lipid 
bilayers is driven by a negative value of enthalpy but opposed by negative entropy. The 
calculated total driving force after the enthalpy gains and entropy losses comes from two 
sources: 1) from the energy of conformational changes during fusion protein folding and 
2) from the energy and entropy due to the insertion of fusion peptide into the lipid 
bilayer. The structures of fusion proteins of different viruses, the protein folding and 
conformational changes are described in the next chapter. 
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F protein structure 
Influenza Hemagglutinin. Influenza virus infects cells by binding to sialic acid 
residues on cell surface molecules and, following transfer into the endosomes by 
receptor-mediated endocytosis, the viral membrane and the endosomal membrane fuse 
together releasing the viral genome into the host cell. Sialic acid binding and viral and 
host cell membrane fusion is mediated by the influenza virus hemagglutinin (HA), which 
is a trimeric integral glycoprotein. HA is probably the most extensively studied viral 
glycoprotein. The 3-dimensional crystal structures of the native protein at neutral pH, the 
fusion active low-pH form and also the uncleaved protein precursor are known (Figure 
5)17 and it serves as a model of viral fusion11 for enveloped viruses. 
HA is a trimer and each HA monomer is composed of two disulfide-linked 
subunits: the receptor binding HA1, which also represents the major antigenic sites of the 
protein and the fusion active HA2 subunits, which contains the N-terminal hydrophobic 
fusion peptide and the C-terminal transmembrane domain13, 18. HA is synthesized as an 
uncleaved HA0 precursor and cleavage primes HA from the native metastable state to the 
fusion active, stabilized low-pH state. In the native form HA2 trimerizes through the 
formation of a parallel coiled coil. At the N-terminus of the native coiled coil a loop 
region connects to a second α-helix, which runs anti-parallel to the first. This second α-
helix contains the transmembrane region at the C-terminus, which anchors the protein to 
the viral membrane. 
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At the N-terminus of the first helix is the hydrophobic fusion peptide, which is 
buried in the center of the native trimer (Figure 6). The three sialic acid-biding HA1 
subunits assemble on the top of the HA2 three-stranded stem and they serve as a clamp. 
 
Figure 5. The conformations of influenza hemagglutinin. Adapted from Skehel et al.17 
 
In the low-pH state, however, a conformation change happens, which is often 
referred as the spring-loaded conformational change13, 19. In acidic environment the loop 
region of HA2 refolds into an α-helix connecting the original helices into one extended 
coiled coil. Now the N–terminal fusion peptide is relocated toward the target membrane 
to promote fusion. (Figure 5)19. 
 23
This dramatic change in the secondary structure has been confirmed by CD 
spectroscopy results, which revealed a change in the α-helical signal of the loop region 
between pH=5 and pH=7. The formation of the extended coiled coil can also be induced 
by elevated temperature at neutral pH. 
Figure 6. Spring-loaded conformational change of influenza HA2. From Carr et al.19 
 
 
The coiled coil structure is not a unique motif, it is found in many other proteins, 
including the leucine zipper domain of some transcription factors. In general the coiled 
coil motifs consist of α-helices that wrapped around each other with a left-handed 
superhelical twist. Coiled coil sequences contain hydrophobic and hydrophilic amino acid 
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residues in a repeating pattern. These regions are called the heptad repeat regions 
(denoted positions from a through g), where the hydrophobic residues occur at the first 
(a) and fourth (d) positions of the repeating pattern and the helices are held together by 
hydrophobic interactions between these amino acids. The heptad repeat is also known as 
the 4-3 hydrophobic repeat and it is the hallmark of coiled coil formation19. 
 
Figure 7. Model for membrane deformation catalyzed by influenza HA. Adapted from 
Blumenthal et al.11 
 
 
The conformation change in the HA2 region is coupled to deformation of the 
target and viral membranes through the fusion peptide and the transmembrane (TM) 
domain, respectively. The second α-helix in HA2, which contains the TM domain at its 
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C-terminus, is in anti-parallel position to the extended coiled coil, so the fusion peptide 
and the TM anchor is on the same side pulling the viral and target membrane close to 
each other for fusion (Figure 7). 
 
HIV gp-160. The structure of the envelope glycoprotein of Human 
Immunodeficiency Virus Type 1 (HIV-1) shows striking similarity to the low pH-induced 
conformation of influenza hemagglutinin. The gp-160 glycoprotein precursor consists of 
a complex of gp-120 and gp41 glycoproteins that are generated by proteolytic cleavage of 
the precursor polypeptide chain. The gp120 is the highly glycosylated receptor-binding 
subunit, it directs target cell recognition and viral tropism through interaction with the 
cell-surface receptor CD4 and with chemokine co-receptors CCR5 and CXCR4. 
Sequence analysis of HIV isolates revealed that gp120 can be organized into variable 
(V1-V5) and conserved (C1-C5) regions. Its primary role is to attach HIV to the target 
cell and bring the virus close to the membrane of these target cells. Once this is achieved, 
the transmembrane protein gp41 mediates the fusion of the viral and target membranes to 
enable genetic information of the virus flow into the target cell. Gp41 is relatively well 
conserved and most of its surface is hidden from antibody recognition before attachment 
and fusion20. Binding to CD4 surface receptors induces conformational changes both in 
the gp120 and gp41 structures. These conformational changes are thought to expose the 
hydrophobic, glycine-rich fusion peptide region of gp41 that is essential for membrane-
fusion activity. Previous studies identified an α-helical region in gp41, which consists of 
a trimer of two interacting peptides (N36 and C34). Crystal structure of this complex 
showed that three peptides N36 form the interior, parallel coiled-coil trimer and three 
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C34 helices are packed into the hydrophobic outside grooves of the inner trimer in anti-
parallel fashion (Figure 8)21. 
 
 
Figure 8. Diagrams of the N36/C34 complex. The left panel shows an end-on view of the 
N36/C34 complex looking down the three-fold axis of the trimer. The right panel shows a 
side view of the complex. The N36 helices (blue) form the inner trimer and their amino-
termini point toward the top of the page. The C34 peptides (purple), located in the surface 
grooves, form the anti-parallel outer helices. Adapted from Chan et al.21 
 
 
Sequence analysis of the gp41 ectodomain also revealed the 4-3 heptad repeat 
pattern with hydrophobic residues at the first (a) and fourth (d) positions of N36 and C34 
peptide regions. However, the generation of stable gp41 trimers for structural and 
immunological studies is very difficult because of the lability of these glycoprotein 
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complexes. Both the intersubunit interactions that promote trimer formation and also the 
association between gp120 and gp41 are labile. Soluble forms of HIV-1 envelope 
glycoprotein have been produced by deletion of the transmembrane region and 
cytoplasmic domain of gp41 and as well as modification of the proteolytic cleavage site 
between gp120 and gp41. These attempts resulted unstable heterogeneous dimers and 
tetramers instead of stable glycoprotein trimers. Other approaches, including introduction 
of cysteine residues22 that form intersubunit disulfide bonds, addition of trimerization 
domains (GCN423, 24 or T4 bacteriophage fibritin25) to the gp41 ectodomain or generation 
of chimeric proteins of HIV-1 gp120 and influenza HA1/HA226 resulted more stable 
constructs with patterns of neutralizing and non-neutralizing antibody binding, but further 
studies are needed to clarify the conformational state of the stabilized HIV-1 envelope 
glycoprotein trimer. 
 
Paramyxovirus F protein. The most straightforward way to better understand the 
mechanism of fusion in paramyxoviruses would be solving the structure of the fusion 
protein by crystallization. To date, the best data that come from crystallized 
paramyxovirus fusion proteins are the partially proteolyzed structure of Newcastle 
disease virus F protein27 and the pre- and post-fusion structures of an uncleaved human 
parainfluenza virus F ectodomain expressed in insect cells15, 28. These models give some 
insight to the structures of paramyxovirus F proteins, but further studies with other viral 
fusion proteins are needed to elucidate the fusion mechanism. 
The Paramyxovirus F genes encode 540 to 580 residues. All Paramyxovirus 
fusion (F) proteins are type I integral membrane glycoproteins, which spam the viral 
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membrane once and contain a signal sequence at their N-terminus. The signal sequence 
directs the growing polypeptide chain to the ER, where glycosylation and post-
translational modifications take place. At the C-terminus the hydrophobic transmembrane 
(TM) domain anchors the protein to the membrane leaving a short (20-40 residues) 
cytoplasmic tail. F proteins are synthesized as single-chain inactive precursors (F0), 
which are subsequently cleaved into the fusion active, disulfide linked F1 and F2 subunits 
by host cell proteases (Figure 9)29. Based on the cleavage site paramyxoviruses can be 
divided into two groups: those that have multiple basic residues at their cleavage site, and 
the ones with only a single basic residue at the cleavage site1, 14. Cleavage of the proteins 
with multiple basic cleavage site occurs in the trans-Golgi, the enzyme that is responsible 
for the cleavage is furin, a subtilisin-like endoprotease, which recognizes a specific 
sequence (R-X-K/R-R). Since furin is a cellular protease in the trans-Golgi network, F 
proteins of the viruses (RSV, NDV virulent strain, measles, SV5, mumps) that have 
multiple basic sites are cleaved intracellularly and delivered to the plasma membrane as 
cleaved and potentially active F proteins. 
 
 
Figure 9. Schematic diagram of RSV F protein. The fusion peptide, heptad repeat regions 
(HR1-3) and transmembrane anchor is shown. Adapted from Lawless-Delmedico et al.29 
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Paramyxoviruses (e.g. Sendai virus) with a single basic residue at the cleavage 
site between F1 and F2 subunits tend to be restricted in the respiratory tract, where the 
necessary protease can be found. The protease, which is responsible for activating 
paramyxoviruses in the respiratory tract, is secreted from Clara cells in the bronchial 
epithelium. The fusion protein is delivered to the plasma membrane as an inactive, 
uncleaved form and cleavage by the extracellular host cell protease activates the fusion 
protein. It has been shown that RSV F protein has two cleavage sites; one at the F1-F2 
junction and the other is in the F2 subunit. For membrane fusion activity RSV F needs to 
be cleaved at both furin cleavage sites30. 
Besides the signal sequence and transmembrane region paramyxovirus fusion 
proteins have several conserved domains that have crucial roles in viral fusion. Right 
after the proteolytic cleavage site at the N-terminus of the F1 subunit is the hydrophobic 
fusion peptide. Similarly to influenza HA and HIV-1 gp41, the fusion peptide is thought 
to be inserted into the target membrane to initiate fusion. Between the fusion peptide and 
transmembrane domain are the 4-3 heptad repeat regions with hydrophobic amino acid 
residues in every a and d position. In paramyxoviruses there are at least two heptad repeat 
domains, but in some cases (e.g. RSV, Sendai, measles, parainfluenza, rinderpest, SV5 or 
NDV) a third heptad repeat region (HR3 or HRC) can be found in the F2 subunit31. The 
role of HR3 has yet to be identified, but it is thought that this domain probably does not 
form helix in the crystal structure of F protein. Crystal structures of many paramyxovirus 
HR cores have been solved previously and all revealed a trimeric coiled coil formation 
beginning near the C-terminal end of the fusion peptide15, 28, 29, 31, 32. The structure of 
paramyxovirus heptad repeat coiled coils also show similarities to other type I viral 
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fusion proteins, such as low-pH induced influenza HA, gp41, Ebola Gp2 or MMLV Env-
TM protein (Figure 10.)32, 33 
 
Figure 10. Top and side views of SV5 F1 core trimer compared to other type I 
glycoproteins, such as the low pH-induced influenza HA (tBHA2), HIV-1 gp41, MMLV 
Env-TM and Ebola Gp2 protein. Interior trimers are shown in grey, exterior helices in 
blue. Adapted from Baker et al.33 
 
The first solved crystal structure of a paramyxovirus F protein was determined by 
Chen et al.27, 34 with an uncleaved F protein from an avirulent strain of Newcastle disease 
virus. It crystallized as a trimer with distinct regions of head, neck and stalk shown in 
Figure 11. The head and neck regions contained sequences from both the F1 and F2 
subunits, the stalk region was a long coiled coil trimer from residues 171 to 221. 
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Figure 11. Space-filling model of NDV F trimer. The left panel shows the side view of 
the trimer with monomers colored differently. Head, neck and stalk regions labeled on 
the left. The right panel shows a top view of the trimer looking down the three-fold axis. 
Adapted from Chen et al.27 
 
 
The structure is missing several crucial domains that would be important to 
understand the fusion mechanism. First, the entire transmembrane domain and 
cytoplasmic tail was eliminated from the structure in order to allow secretion of the 
mutated F protein from the cells. This may be important, since expression of a mutant 
NDV F protein missing the cytoplasmic region resulted in decreased efficiency of 
cleavage and surface expression. The region from amino acid residues 106 to 170 is also 
missing from the construct. This important region contains the cleavage site, the fusion 
peptide and the amino terminal half of the HR1 region. Another missing region from 
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residues 455 to 499 includes the entire HR2 domain, which might be the result of protein 
degradation. These missing domains complicated consideration of the structure of the 
pre- and post-fusion conformation of the NDV F protein and raised many questions about 
the conformational changes required for fusion activation14. 
The crystal structure of the uncleaved human parainfluenza virus 3 F protein 
ectodomain (hPIV 3) was determined in 2005 by Yin et al.28, 32. The construct was 
truncated right before the membrane anchor domain and protein was expressed in insect 
cells by using the baculovirus expression system. The crystal structure of hPIV3 F 
showed a trimer with the head, neck and stalk regions previously determined in NDV F, 
and it also contains the complete six-helical bundle coiled coil core, which was not 
observed in NDV F (Figure 12). The only part that was missing from this structure was 
the cleavage site between F1 and F2 and probably because of that the fusion peptide 
could not be located in the structure. Although the fusion peptide was not at the 
appropriate end of the heptad-repeat coiled coil and the polypeptide chain was intact, the 
trimeric hPIV 3 F structure was thought to be the post-fusion conformation of the protein. 
However, the crystal structure of the hPIV 3 F also raised further questions. First, it was 
not known, what the pre-fusion conformation of the paramyxovirus F protein was and 
how stable this formation was. Second, it was also not clear how membrane fusion could 
be achieved by the post-fusion state, because the cleavage site was disrupted in the 
construct and according to fusion models this proteolytic cleavage would allow 
repositioning of the fusion peptide toward the target membrane. And third, since the 
transmembrane region was missing, the role of the TM domain in the stability of the pre-
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fusion state and in the conformational change during the transition between the pre-and 
post-fusion forms also remained unsolved. 
 
 
Figure 12. Structure of the hPIV 3 F ectodomain. A) Schematic of the domain structure 
of hPIV 3 F. Colors correspond to those used in Figure 12. B. B) Ribbon diagram of 
hPIV F trimer. The six-helix bundle of the heptad repeats is labeled as 6HR C) Surface 
representation of hPIV 3 F trimer. Monomers are colored differently. Head, neck and 
stalk regions are shown in the middle. Adapted from Yin et al.28  
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In 2006 Yin et al. published another paramyxovirus F protein crystal structure. 
They published the structure of the parainfluenza virus 5 (previously known as SV5) F 
protein in its pre-fusion conformation. Since the soluble SV5 F ectodomain did not 
trimerize efficiently a trimerization domain (GCNt) was engineered C-terminal to the 
HRB region. Trimerization domains have been successfully attached to influenza HA and 
HIV gp41 to help the formation of stable trimers and the SV5 F-GCNt construct indeed 
formed stable trimers. Comparison of the pre-fusion SV5 and the post-fusion hPIV 3 F 
protein structures shows striking differences (Figure 13). The first obvious differences 
are the position of the stalk region relative to the head and the size of the head regions. In 
the post-fusion orientation the head is more compact and the stalk is flipped to the other 
side of the head turning the whole structure upside-down. The second striking difference 
is the conformation of the HRA region in pre-and post-fusion states. In the pre-fusion 
form HRA is folded around the DIII core (Figure 13.c) containing short helical and β-
sheet segments. In the post-fusion form HRA folds into a single strand of a long helix, 
pulling HRB to the other side of the head and forming six-helical bundle coiled coil core. 
It is interesting that in this structure the HRB heptad-repeat residues form the three 
helical bundle stalk region in the pre-fusion state along with the GCNt trimerization 
motifs, however, isolated HRB peptides alone don’t form stable trimers in aqueous 
solutions. This suggests that the GCNt domain, or the transmembrane region and 
cytoplasmic tail in the natural protein stabilize the HRB stalk as well as the prefusion 
conformation state. 
Based on the pre-fusion and post-fusion crystal structures Yin et al. proposed an F 
protein-mediated fusion model for paramyxoviruses (Figure 14)35. 
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 Figure 13. Pre- and post-fusion F protein conformations. a. Ribbon diagram of SV5 F-
GCNt trimer (pre-fusion). b. Ribbon diagram of hPIV 3 F trimer (post-fusion). c. and d. 
Ribbon diagrams of single monomers of SV5 F and hPIV 3 F, respectively. Adapted from 
Yin et al.35 
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In this model starting from the pre-fusion state (Figure 14 a), the first step is 
when the HRB helices break the interactions with the head region and form the ‘open 
stalk’ intermediate (b). The HRA region is still in its pre-fusion conformation; no coiled 
coil is formed yet. In the next step (pre-hairpin intermediate, c) the HRA region is flipped 
over the head and forms coiled coil helices relocating the fusion peptide toward the target 
membrane. Refolding of the HRB region into an α-helical structure (d) and the six-
helical bundle formation pulls the target membrane close to the viral membrane resulting 
pore formation and the post-fusion protein structure (e). 
 
 
Figure 14. Model for F-mediated membrane fusion. See explanation in the text above. 
Adapted from Yin et al.35 
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CHAPTER II 
 
CLONING, EXPRESSION AND PURIFICATION OF HUMAN 
METAPNEUMOVIRUS FUSION GLYCOPROTEIN 
 
2.1. Introduction 
Sequence analysis of hMPV F clearly showed homologous regions to other 
paramyxovirus fusion proteins and we hypothesized that these regions might have similar 
functions. Based on the hMPV F sequences we predicted that the hMPV fusion protein 
monomer is approximately 58 kDa in size. There is a potential single basic cleavage site 
between F1 and F2 subunits, which is homologous to that in hPIV-1 and Sendai virus. 
Further, we found that the fusion peptide region right after the cleavage site shows high 
sequence homology to that of hPIV-1, Sendai and hRSV. Using secondary structure 
predicting algorithms (such as LearnCoil-VMF, MultiCoil, ParaCoil), which are 
specifically designed to predict the propensity of a protein sequence to form coiled coil, 
we identified HR1 and HR2 heptad repeat regions in the amino acid sequence. Now we 
had strong evidence, based on the predicted amino acid sequences that significant 
homology exists between hMPV F and other paramyxovirus fusion glycoproteins. To 
study the structural and biochemical properties of hMPV fusion protein, we needed a 
stock of purified hMPV F protein expressed in mammalian cells. We wanted to use 
mammalian cell lines (instead of expression in bacteria or insect cells) to make sure that 
our protein is glycosylated and folded correctly or close to its native conformation. 
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For protein expression we tried several approaches, the first strategy was to use an 
inducible T7 vaccinia virus expression system. For that approach, cDNA of hMPV F 
protein was generated by RT-PCR from isolate TN/92-4 (A2 strain) and cloned into pET-
11KC36 vector, in order to add C-terminal 6xHistidine tag and BirA biotinylation site. 
The hMPV F insert with the fused His-tag and BirA site was excised from pET-11KC by 
restriction sites flanking the cloning sites and the whole construct was subcloned into 
pVOTE.1 vaccinia virus vector37 (Figure 15). A recombinant vaccinia virus was 
generated, using standard infection/transfection protocols (see section 2.2. Generating 
recombinant vaccinia virus stock), by homologous recombination of the vector, which 
contains vaccinia virus sequence flanking the inserted F gene and the infecting vaccinia 
virus strain. The pVOTE.1 vector contains the gpt gene, which encodes for mycophenolic 
acid (MPA) resistance, allowing selection for recombinant vaccinia virus by using MPA-
containing selective medium. 
The vector also encodes for a bacteriophage T7 polymerase gene. T7 is a single 
subunit RNA polymerase that recognizes a highly conserved promoter sequence, so 
synthesis of T7 RNA polymerase by a recombinant vaccinia system allows high-level 
expressions of genes placed next to the T7 promoter within a transfected plasmid. 
Previously an inducible expression of a reporter gene under T7 promoter control has been 
generated when incorporated into a recombinant vaccinia virus, vT7lacOI, which 
contains the E. coli lac repressor (lacI) gene, regulated by the vaccinia virus early/late 
promoter and the bacteriophage T7 RNA polymerase gene (gene 1) regulated by a 
modified perfect palindromic E. coli lac operator (lacO) placed several nucleotide 
downstream of vaccinia virus late promoter37 (Figure 15). 
 39
  
Figure 15. Regulation of target gene expression in the absence (-) or presence (+) of 
inducer. PE/L is the vaccinia virus early/late promoter, T7 gene I is the bacteriophage T7 
polymerase gene, SLO is the modified lac operon and PT7 is the T7 promoter. From Ward 
et al.37  
 
In our expression system hMPV F gene expression was induced by the addition of 
isopropyl β-D-thiogalactopyranoside (IPTG) (see section 2.2. IPTG-induced protein 
expression). 
The second method that we tried for recombinant hMPV F protein expression is 
using codon optimized F sequence for cloning and a mammalian expression vector 
system designed for visual detection of transfected mammalian cells. Codon optimization 
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is a method for replacing one or more codon that is rarely used in the host with one that is 
more frequently used. Elimination of codon that would be read as termination signals, 
cis-acting negative regulatory elements or different amino acids in the host is essential to 
improve protein expression, especially in case of viral proteins. Codon optimization also 
increases the stability of mRNA, optimizes the RNA secondary structure and DNA GC 
content, eliminates common restriction enzyme sites and repetitive elements from the 
sequences. These all enhances the expression level of the recombinant protein. To 
produce a soluble form of hMPV F protein (FΔTM), the codon-optimized full-length F 
gene was PCR amplified using primers that amplified the sequence without the predicted 
hydrophobic transmembrane region and cytoplasmic domain. So, we had two sets of 
optimized F gene, one for membrane bound full-length F expression, and another to 
produce soluble truncated hMPV F (FΔTM). For expression vector we chose pTracer-
EF/V5-His (Invitrogen) with a human elongation factor (hEF) and human 
cytomegalovirus immediate/early (CMV) promoter, a C-terminal improved Green 
Fluorescent Protein (GFP) gene and V5 epitope and 6xHistidine tag. Detection of 
transfected cells is possible because of the GFP expression and 6xHistidine tag is for 
metal ion affinity purification purposes (Figure 16). With that we were able to detect 
expressed full-length F protein bound to the transfected cell membrane, and also soluble 
FΔTM expressed in the culture media. Although protein expression level was moderate, 
this was the first successful attempt to produce and purify hMPV F protein. 
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 Figure 16. Schematic diagram of pTracer-EF/V5-His mammalian expression vector. 
(Invitrogen) 
 
 
The best method for protein expression was the third one, when we changed the 
cell line and also chose a different expression vector. Instead of using adherent 
mammalian cells (e.g. HEp-2 or LLC-MK2) we used a suspension adapted mammalian 
cell line, FreeStyle 293-F from Invitrogen, which grows in serum-free culture medium, 
and allows high level of protein expression. The optimized full-length F and FΔTM gene 
was cloned into pcDNA3.1/myc-His expression vector (Invitrogen) with C-terminal c-
myc epitope and 6xHistidine tag (Figure 17). We found that the peak of expressed FΔTM 
protein production was 96 h post-transfection and protein was detected mostly in the 
culture media and smaller amount in the cell lysate. For structural and biochemical 
analyses this F protein construct has been studied and all experiments detailed in the 
following sections used FΔTM protein expressed with the pcDNA3.1-FreeStyle 293-F 
expression system. 
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 Figure 17. Schematic diagram of pcDNA3.1/myc-His expression vector. (Invitrogen) 
 
Since the FreeStyle 293-F expression medium is a serum-free medium, 
purification of the expressed FΔTM protein was done from the culture media by using 
immobilized metal ion affinity chromatography. The 6xHistidine tag at the C-terminus of 
the construct has high affinity to nickel (Ni2+) ions immobilized on a Sepharose column. 
We used HisTrap 1ml or 5ml Nickel-Sepharose columns (GE Healthcare) operated either 
with syringe or with ÄKTAdesign automated FPLC system. 
 
2.2. Materials and Methods 
Vaccinia virus expression system 
Cells, viruses, expression vector. BSC-40 cells were maintained at 37 °C and 5% 
CO2 in Eagle’s MEM medium supplemented with 10% fetal bovine serum. Vaccinia virus 
(vT7lacOI) was obtained from Dr. Crowe’s lab (Vanderbilt University), pVOTE.1 
 43
vaccinia vector was obtained from MedImmune Inc., Gaithersburg, MD, and PCR 
primers were ordered from Invitrogen. 
Cloning hMPV F gene into pVOTE.1 vector. The full-length F sequence from 
isolate TN/92-4 was cut out from pET-11KC vector and ligated with T4 DNA ligase into 
pVOTE.1 vector between Nco I and BamH I multiple cloning sites. Ligation reaction was 
transformed into E.coli DH5α strain, bacteria were plated on LB/Ampicillin plates and 
colonies were picked, plasmid DNA was purified with QIAprep Miniprep Kit 
(QIAGEN). DNA sequencing by Vanderbilt DNA Sequencing Core Facility confirmed 
successful ligation. 
Generating recombinant vaccinia virus stock. BSC-40 cell monolayer in T75 
culture flask was infected with trypsinized vT7lavOI vaccinia virus (1.5x105 pfu/ml) and 
incubated for 2 h at 37 °C and 5% CO2. Medium was removed, cells were washed with 
phosphate buffered saline (PBS, Gibco) and cell were transfected with pVOTE.1-F 
plasmid DNA using Effectene transfection reagent (Qiagen). Infected/transfected BSC-40 
cells were incubated for 2 days at 37 °C and 5% CO2. 
Plaque purification of recombinant virus. 2 days post-infection cells were 
removed from culture flask by scraping and centrifuged at 1800 rpm for 5 min. Old 
media was discarded and cells were resuspended in 1.0 ml fresh medium. 500 µl infected 
cells were mixed with 500 µl 0.025 mg/ml trypsin and incubated in water bath at 37 °C 
for 30 min and vortexed every 5-10 min. Recombinant virus stock was sonicated for 30 
sec twice on ice. BSC-40 cell monolayer was infected with recombinant virus stock in 10 
fold dilutions for 2 h then overlayed with 2% low melting agarose/selective medium 
containing: mycophenolic acid (MPA), xanthin, hypoxanthin. Agarose was let stand to 
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solidify and plates were incubated for 2 days at 37 °C and 5% CO2. Second agarose layer 
with 1% neutral red (from 10mg/ml neutral red stock) was overlayed and plates were 
incubated overnight. Recombinant vaccinia virus plaques were picked on the next day. 
Cells were trypsinized, sonicated (see above) and plaque purification was repeated two 
more times with selective medium. Final recombinant virus titer was determined by 
plaque assay. 
IPTG-induced protein expression. BSC-40 cell monolayer was infected with 
recombinant vaccinia virus containing hMPV F gene in the presence of 2.0 mM IPTG to 
induce F protein expression. Cell were incubated for 2 days then harvested and lysed. 
Cell lysate was run on SDS PAGE gel for Coomassie staining and Western blot to test for 
F protein expression. 
 
Protein expression with pTracer vector 
Cells, expression vector, PCR primers, restriction enzymes. LLC-MK2, HEp-2 
and 293-T cells were maintained in Opti-MEM medium with 2% FBS at 37 °C and 5% 
CO2. Expression vector pTracer-EF/V5-His was purchased from Invitrogen. Restriction 
enzymes Kpn I and Not I were purchased from New England Biolabs (NEB). PCR 
primers were ordered from Invitrogen. 
Cloning hMPV F and FΔTM into pTracer vector. Full length F sequence was 
obtained from isolate TN/92-4 by RT-PCR and sequence optimized by a commercial 
source (Aptagen). Optimized hMPV F sequence was amplified with forward and reverse 
PCR primers to introduce Kpn I and Not I restriction enzyme sites at 5’ and 3’ ends, 
respectively. Vector and PRC-amplified F sequence was digested by restriction enzymes 
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and ligated together using T4 DNA ligase. Ligation reaction was transformed into DH5α 
E.coli strain, bacteria were plated on LB/Ampicillin plates, colonies containing the 
pTracer-F plasmid were picked, and plasmid was purified with QIAprep Miniprep Kit 
(QIAGEN). DNA sequencing at Vanderbilt DNA Sequencing Core Facility confirmed 
that plasmids contained the F insert and it has been cloned in frame. 
Detection of hMPV F and FΔTM. LLC-MK2, HEp-2 and 293-T cells were 
transfected with the pTracer-F of pTracer-FΔTM constructs using Effectene Transfection 
Reagent (QIAGEN) as recommended by the manufacturer. 24-48 h post-transfection cells 
were fixed with 80% methanol and stained with anti-hMPV polyclonal guinea pig serum 
and Alexa Fluor 568-conjugated goat anti-guinea pig secondary antibodies. Stained cells 
were examined on a Nikon Diaphot inverted microscope. To detect GFP expression in 
transfected cells, fixed cell monolayer was irradiated with 400 nm light and cells were 
analyzed on a Nikon Diaphot microscope and photographed with a Nikon D1000 digital 
camera For Western blot detection transfected cells were harvested by scraping, 
centrifuged and supernatant was removed for gel electrophoretic analysis. Cell pellet was 
resuspended in lysis buffer (50 mM Tris-Cl, 140 mM NaCl, 1.5 mM MgCl2, 0.5% NP-40 
and PMSF) and lysed on ice for 15 min. Cells were centrifuged again for 15 min and cell 
lysate was removed and analyzed with Western blot technique. Mouse anti-polyHistidine 
monoclonal antibodies and anti-hMPV polyclonal guinea pig serum were used as primary 
antibodies for Western blot detection. 
 
 
 46
F expression with pcDNA3.1/myc-His vector 
 
Cells, expression vectors, PCR primers, restriction enzymes. Freestyle 293-F cells 
were purchased from Invitrogen, and maintained in Freestyle 293 Expression medium at 
37 °C and 5% CO2 in suspension. Cells were continuously rotated on an orbital shaker 
platform at 125 rpm. pcDNA3.1/myc-His B vector was ordered from Invitrogen. PCR 
primers were ordered from Invitrogen and reconstituted in our laboratory by preparing a 
20 µM stock. Kpn I, Not I, BamH I restriction enzymes were ordered from New England 
Biolabs, Apa I from Promega. 
Cloning of hMPV F full-length and hMPV F ectodomain. We used RT-PCR to 
amplify a full-length F sequence from isolate TN/92-4, a prototype A2 lineage strain 
according to the proposed nomenclature. The forward and reverse primers that were used 
for PCR amplification are the following: 5’-CAAGAACGGGACAAATAAAAATG-3’ 
and 5’-CTAATTATGTGGTATGAAGCC-3’. The full TN/92-4 F sequence was 
sequence-optimized by a commercial source (Aptagen) to alter suboptimal codon usage 
for mammalian tRNA bias, improve secondary mRNA structure and remove AT-rich 
regions, increasing mRNA stability. The optimized full-length F sequence was cloned 
into the mammalian expression vector pcDNA3.1 (Invitrogen) to generate the construct 
pcDNA3.1-F. To generate the hMPV F ectodomain construct (pcDNA3.1-F∆TM) the 
optimized full-length cDNA of the F gene was PCR amplified with primers 5’-
GGAGGTACCATGAGCTGGAAG-3’ and 5’-GAAGCGGCCGCTGCCCTTCTC-3’ 
and PCR product was digested and ligated into the KpnI/NotI sites (restriction sites 
underlined in primer sequences) of vector pcDNA3.1/myc-His B (Invitrogen). Ligations 
were transformed into E.coli strain DH5α competent cells, and plasmids were purified 
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with the QIAprep Miniprep Kit (QIAGEN). All plasmid constructs were sequenced on an 
ABI 3730xl DNA Analyzer in the Vanderbilt DNA Sequencing Core Facility to confirm 
in frame cloning with the C-terminal c-myc epitope and polyhistidine (6xHis) tag of the 
expression vector. 
HMPV F ectodomain expression in mammalian cells. The pcDNA3.1-F∆TM 
recombinant plasmid was transfected into suspension 293-F cells as recommended by the 
manufacturer (Freestyle 293 Expression System, Invitrogen). Both the cell fraction and 
the supernatant were assayed by SDS-PAGE and Western blot for F∆TM protein at 24, 
48, 72 and 96 hours. At indicated time points post-transfection, cells were centrifuged for 
5 min at 100 x g at room temperature and the supernatant and cells harvested separately. 
Supernatant was additionally filtered through 0.2 μm filters before purification. Cells 
were lysed in lysis buffer consisting of 50 mM Tris-Cl, 140 mM NaCl, 1.5 mM MgCl2, 
0.5% NP-40 and PMSF protease inhibitor cocktail (Sigma). 
Purification of 6xHis-tagged F ectodomain. Protein purification was performed 
on an ÄKTA FPLC system controlled by UNICORN 4.12 software (GE Healthcare). The 
His-tagged F ectodomain F∆TM was purified by immobilized metal ion affinity 
chromatography using pre-packed HisTrap Ni-Sepharose columns (GE Healthcare). 
Sample was diluted with concentrated binding buffer stock to adjust pH, salt and 
imidazole concentration before purification. Protein was loaded on a 5 ml HisTrap 
column with a loading flow rate of 5.0 ml/min, and the binding buffer contained 20 mM 
sodium phosphate, 0.5 M NaCl, 30 mM imidazole (pH 7.4). Wash and elution protocols 
were extensively optimized for imidazole concentration and wash/elution column 
volumes (data not shown). Unrelated proteins were eluted in Elution Step 1 using 4 
 48
column volumes of 6% elution buffer, and the 6xHistidine-tagged F protein was eluted in 
Elution Step 2 with 4 column volumes of 25% elution buffer. The elution buffer 
contained 20 mM sodium phosphate, 0.5 M NaCl, 500 mM imidazole (pH 7.4). Purified 
protein was concentrated and dialyzed against PBS (Invitrogen) through Amicon Ultra 
centrifugal filters with 30,000 MWCO (Millipore). 
Gel electrophoresis, Coomassie staining and Western blot. Purified protein 
fractions were loaded on NuPAGE 4-12% Bis-Tris Gel (Invitrogen) and run at 200 V 
constant voltage in MES-SDS running buffer (Invitrogen). Under native conditions 
protein was loaded on 4-12% Tris-Glycine gel and gel was run at 85 V constant voltage 
at 4°C. Gels were stained with Simply Blue SafeStain (Invitrogen) or Silver Stain Plus 
(Bio-Rad) to visualize protein bands. For Western blot analysis, separated protein bands 
were transferred to Invitrolon PVDF membrane (Invitrogen) at 30 V for 1 h. After 
blocking with 5% milk in Tris-buffered saline with 0.05% Tween-20 (TBS-T), 
membranes were incubated with anti-polyhistidine mouse monoclonal antibody (Sigma) 
and anti-hMPV polyclonal guinea pig serum at a 1:500 dilution. Anti-hMPV guinea pig 
serum was generated in our laboratory as described by Williams et al38. Membranes were 
washed with TBS-T and incubated with horseradish peroxidase-conjugated goat anti-
mouse or goat anti-guinea pig secondary antibodies (Southern Biotech). Membranes were 
again washed with TBS-T and developed with TMB Membrane Peroxidase Substrate 
(KPL). 
Immunofluorescent detection of expressed F protein. LLC-MK2 cell monolayers 
were transfected with pcDNA3.1-F recombinant plasmid by using TransFectin Lipid 
Reagent (Bio-Rad). At 24 h after transfection cells were fixed with 80% methanol, 
 49
washed with PBS-T then incubated with anti-hMPV polyclonal guinea pig serum in PBS-
T/milk (1:500 dilution) for 1 h at 37 °C. After washing with PBS-T, cells were stained 
with AlexaFluor568-conjugated goat anti-guinea pig Ig or AlexaFluor568-conjugated 
goat anti-rat Ig antibody (Molecular Probes) in PBS-T/milk for 1 h at 37 °C. Monolayers 
were examined on an inverted Nikon Diaphot microscope and images captured with a 
Nikon D1000 digital camera. 
2.3. Results 
We generated recombinant vaccinia virus stock and passaged plaque-to-plaque 
three times to ensure clonality. Infected cell lysate was analyzed by Western blot 
technique using anti-hMPV polyclonal guinea pig serum as primary antibody. hMPV F 
expression was minimal in infected BSC-40 cells even at the highest (2.0 mM) IPTG 
concentration, as detected by Western blot (data not shown). Cell viability was low in 
MPA-containing selective medium, which may have been one reason for low protein 
expression. 
The sequence optimization strategy was undertaken to enhance expression of 
hMPV F in mammalian cells. The codon-optimized F sequence was expressed in 
moderate amounts when cloned into pTracer plasmid and transfected into adherent 
mammalian cells (293-T, HEp-2, LLC-MK2). We successfully detected it with anti-
hMPV guinea pig serum by immunofluorescence (Figure 18 B) or Western blot (data not 
shown). Transfection efficiency has been monitored by GFP expression in transfected 
cells upon irradiation with 400nm light, as shown in Figure 18 A. While the full-length F 
protein was localized in the cell membrane, FΔTM ectodomain was detected mostly in 
the membranes of cellular compartments (ER, Golgi) in the cytoplasm. 
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In contrast, the sequence-optimized construct in pcDNA3.1 vector was expressed 
at high levels when transfected into LLC-MK2 cells. Furthermore, full length F protein 
was detected by immunofluorescence in a membrane distribution similar to that observed 
in hMPV-infected cells. The predicted molecular weight of the full-length hMPV F 
protein based on the nucleotide sequence is 58 kDa, the F ectodomain, without the 
transmembrane and cytoplasmic regions, is 56 kDa. The supernatant of transfected 293-F 
cells has been purified in 2 steps with different imidazole concentrations in the elution 
buffer. In the first elution step unrelated proteins have been eluted off the column, using 
30mM imidazole concentration. In the second step hMPV FΔTM has been eluted with 
125mM imidazole concentration in the binding buffer. 
SDS-PAGE and immunoblot analysis of pcDNA3.1-F∆TM–transfected 293-F 
cells showed that the hMPV F ectodomain (F∆TM) was present in the medium rather 
than the cell lysate. After affinity purification with HisTrap column F∆TM protein was 
highly pure as determined by Coomassie blue and silver staining of SDS-PAGE gels 
(Figure 19 A). Denaturing, non-reducing SDS-PAGE and immunoblot analysis of 
transfected cells showed that the majority of the hMPV F protein was detected as a 
monomer (Figure 19 B, C), and both mouse anti-polyHistidine monoclonal antibody 
(Sigma) and our anti-hMPV polyclonal guinea pig serum detected the protein on Western 
blot. Under native, non-denaturing conditions F protein has been detected as trimer or 
higher size oligomers (Figure 20) and under reducing conditions (Figure 21) it has been 
detected as a monomer, which is cleaved into F1 (approx. 45 kDa) and F2 (11 kDa) 
subunits. 
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 A) 
 
 
 
 
B) 
Figure 18. HMPV F∆TM expression in LLC-MK2 cells using pTracer expression vector. 
A) Transfection efficiency was monitored by Green Fluorescent Protein (GFP) 
expression. B) Immunofluorescence detection of hMPV F∆TM. LLC-MK2 cells are 
stained with polyclonal anti-HMPV guinea pig serum. Pictures were taken on an inverted 
Nikon Diaphot microscope with a Nikon D1000 digital camera. 
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Figure 21 shows a picture of hMPV FΔTM on a Coomassie blue stained 4-12% 
SDS gel. The picture has been taken at Oak Ridge National Laboratory (ORNL) before 
and after a Small Angle X-ray Scattering (SAXS) experiment. F1 and F2 subunits can be 
detected under reducing conditions (lanes 2 and 4). In lane 4 (after SAXS) a fragment 
with 38 kDa size appeared on the gel, possibly the result of protein degradation during 
the experiment. The antiserum we used to detect recombinant F protein in both 
immunofluorescent and immunoblot assays was generated previously by infecting guinea 
pigs with live hMPV. F protein was also detected with both immunofluorescent and 
immunoblot assays by human serum with an hMPV-neutralizing titer of 1:640 (data not 
shown). 
Appendix A shows a sample chromatogram and method section of the two-step 
purification process with the UV absorbance of the loaded sample, wash and eluted 
fractions. We used 1ml or 5 ml HisTrap columns depending on the original sample 
volume with 1.0ml/min or 5.0ml/min sample loading flow rate, respectively. After the 
supernatant containing F protein has been loaded on the column (X1-X6 fractions), 
unbound sample was washed off with 2-column volume binding buffer (20mM 
imidazole). Then 4-column volume of elution buffer with 30mM imidazole was used to 
elute unrelated protein in fractions A1-A2 (first elution step). Another 4-column volume 
of elution buffer with 125 mM imidazole content eluted hMPV F corresponding to an 
increase in the UV signal in fractions A3-A4 (second elution step).  
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 A) 
 
B) 
Figure 19 Purified FΔTM under denaturing, non-reducing conditions. F protein band is a 
monomer with 56 kDa MW. A) Silver stained Bis-Tris 4-12% SDS gel, Lane 1: MW 
marker, lane 2: original supernatant, lane 3: purified protein fraction, lane 4: flow-
through after filtration with a 50 kDa MWCO filter, lane 5: final protein fraction. B) 
Western blots of FΔTM with anti-polyHistidine and anti-hMPV antibodies, respectively. 
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 B) 
A) 
Figure 20. Purified FΔTM under native conditions. A) Diluted and B) undiluted purified 
protein loaded on Tris-Glycine gel. Diluted protein has multiple bands in the range of 120 
kDa-250 kDa suggesting different oligomeric forms. Undiluted protein band shows a 250 
kDa highly aggregated state. No monomer was detected. Anti-polyHistidine monoclonal 
antibody has been used for Western blot detection. 
 
 
Figure 21. FΔTM under denaturing conditions. Lanes 1 and 3: denaturing, non-reducing, 
Lanes 2 and 4: denaturing, reducing conditions (F1 and F2 subunits). Picture was taken 
by Kevin L. Weiss (ORNL) before (Lanes 1, 2) and after (3, 4) SAXS experiment. 
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2.4. Discussion 
We tried several different strategies to produce hMPV F glycoprotein in 
mammalian cells. Other paramyxovirus recombinant fusion proteins (e.g. hPIV-3 or SV5 
F protein) were previously expressed in insect cells using the baculovirus expression 
system28, 35 or the IPTG-induced vaccinia virus system. 
For us the most successful method was when the codon-optimized sequence of 
hMPV F ectodomain was cloned in pcDNA3.1/myc-His expression vector and expressed 
in 293-F suspension adapted mammalian cells. FΔTM was secreted in a soluble state and 
could be detected as a 56 kDa monomer under denaturing conditions. The protein was 
cleaved and F1 and F2 subunits were detected under reducing conditions, as it was 
expected based on the position of the predicted putative cleavage site and the sequence 
homology with other paramyxovirus F proteins. Successful fusion of the paramyxovirus 
membrane with the host cell requires cleavage activation of the F protein1, 28. Following 
activation, the hexameric core is formed through conformation changes and the fusion 
peptide is inserted into the target membrane. The cleavage activation in the hMPV F 
construct makes all these changes possible, and suggests that our protein is capable for 
the conformation change necessary for fusion.  
It is likely that the truncated ectodomain does not form a completely stable trimer 
and the results of our purification optimization strategy support this hypothesis. Gel 
electrophoresis results showed that under native, non-denaturing conditions multiple 
bands could be detected, which suggests that the protein is expressed as a mixture of 
multiple oligomers. The predicted molecular weight of an FΔTM trimer is 168 kDa, yet 
the majority of the purified protein could be passed through a 100,000 molecular weight 
 56
cut-off membrane with little retention (data not shown). These results suggest that while 
FΔTM is capable of forming trimers, trimerization may be a concentration-dependent 
equilibrium, where a highly concentrated protein stock would form more trimers and less 
dimers or other oligomers. Optimizing salt and detergent concentration or choosing 
different protein storage buffer that may reduce protein aggregation and promote trimer 
formation could be another strategy to produce stable trimers. 
Also, the transmembrane domain and cytoplasmic tail might have a stabilizing 
effect on trimer formation, but since they were removed in order to generate a soluble 
protein, FΔTM might be unable to trimerize without the TM region. The same problem 
was reported in case of HIV gp4122-25, SV5 F35 or hPIV-3 F28 ectodomains. To solve this 
issue a variety of trimerization domains were introduced in the fusion protein ectodomain 
constructs to help trimer formation. In further studies an hMPV FΔTM construct fused 
with a trimerization domain (e.g. GCNt or T4 bacteriophage Fibritin)24, 25 might form 
more stable trimers. 
The overall quality, yield and purity of our hMPV F construct were comparable to 
the previously reported recombinant paramyxovirus fusion protein constructs. The yield 
of protein expression was similar to the yield that could be achieved with baculovirus 
expression. Affinity purification using the 6xHistidine tag gave us reasonably pure 
protein stock, although further purification techniques (e.g. size exclusion or ion 
exchange chromatography) could be use to improve protein purity. We could also utilize 
the c-myc-epitope attached to the C-terminal end of our construct for purification or 
protein detection purposes. 
 57
The hMPV F ectodomain was detected by immunofluorescence and immunoblots 
using guinea pig antiserum generated by infection with live virus, and by human 
convalescent serum. These results suggest that FΔTM may be conformationally intact or 
it retains at least some of the epitopes that are present in the native viral protein and are 
important for antigen-recognition by hMPV-specific antibodies. The current hMPV 
FΔTM construct could be a good subject for epitope mapping experiments and/or to 
generate neutralizing or non-neutralizing anti-hMPV monoclonal antibodies. 
Furthermore, because of the antigenic epitopes presented on FΔTM, it is a valuable 
reagent for serological testing, such as enzyme-linked immunosorbent assay (ELISA) to 
detect hMPV infection sensitively and specifically. 
The same overall strategy of recombinant protein expression that we developed 
for hMPV F and similar affinity purification methods can be applied to produce other 
transmembrane proteins. In our lab we also successfully expressed and purified RSV F, 
hMPV G protein and influenza HA ectodomain, but the cloning, expression and 
purification steps have been optimized for each protein specifically. 
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CHAPTER III 
 
STRUCTURAL CHARACTERIZATION OF HMPV FUSION PROTEIN 
 
3.1. Introduction 
Sequence analysis of hMPV F using algorithms such as LearnCoil-VMF, 
MultiCoil or PairCoil gave some insight to the predicted secondary structure of the fusion 
protein. Based on the predicted helices, homology models and scoring matrix results, 
which aligned and compared F protein sequences from 12 paramyxoviruses to the hMPV 
F sequence, Scott Miller39 at the Department of Chemistry at Vanderbilt University 
identified the heptad repeat fusion core in hMPV F and synthesized 21-mer short, 
overlapping peptides from the 43-mer (residues 130-172) HR-1 and 33-mer (454-486 
residues) HR-2 regions. CD spectrum of HR-1 peptides in PBS showed a lack of helical 
structure, which was surprising, since HR-1 peptides from other viral fusion proteins had 
significant α-helical content. Adding trifluoroethanol (TFE) to the original phosphate 
buffer to induce helix formation resulted a strong signal in the helical spectrum. HR-2 
peptides displayed little secondary structure by CD spectroscopy, which was consistent 
with previous reports from other viral fusion cores. However, CD spectrum of an 
equimolar mixture of HR-1 and HR-2 peptides following a freeze/thaw cycle revealed a 
significant increase in the α-helical content suggesting that HR-1 and HR-2 peptides 
indeed form the putative coiled coil secondary structure. Thermal stability and melting 
experiments of the synthetic heptad repeat fusion core gave a Tm ∼ 90 °C, which is 
consistent with the previously reported Tm of RSV hexameric core (88 °C). It has been 
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previously shown that peptides synthesized from other viral fusion protein heptad repeat 
cores have potent inhibitory effects on viral propagation and fusion. Miller showed that 
HR-2 peptides inhibit viral growth with an EC50 ∼ 165 nM. Surprisingly, HR-1 peptides 
also showed inhibitory effect and it was at least 1000 times more potent (EC50 ∼ 46 nM) 
than the previously reported HR-1 peptides from other paramyxoviruses. 
Gel electrophoretic results and Western blots of the purified F ectodomain 
showed that hMPV F protein forms oligomers under native, non-denaturing conditions, 
which fall apart into monomers in denaturing gel. We also found out that the protein is 
cleaved, and F1 and F2 subunits are present in the structure. However, we had no 
information (other than the synthetic HR-1/HR-2 peptide results) about the protein 
secondary structure, the presence and positions of α-helices and coiled coils. Based on 
the amino acid sequence we found 14 cysteines in the protein, but we did not know if 
they all form disulfide bonds and what the bonding pattern looks like. N-glycosylation 
site-predicting algorithms (e.g. NetNGlyc 1.0 Server by CBS) found 3 potential N-
glycosylation sites based on the Asn-Xaa-Ser/Thr triplet. Furthermore, guinea pig and 
human anti-hMPV polyclonal serum recognized the F ectodomain by 
immunofluorescence and on immunoblots, but we needed information about hMPV-
specific monoclonal antibody affinity to F and the kinetics of antibody-antigen binding. 
In this chapter we show several methods and results that help to understand the 
structure of hMPV F protein. For all experiments we used our purified hMPV F 
ectodomain expressed in 293-F mammalian cells. To determine the secondary structure 
of the protein and α-helical content we used circular dichroism (CD) spectroscopy. 
Surface plasmon resonance (SPR) method was used to analyze monoclonal antibody-
 60
hMPV F binding and kinetics. N-glycosylation sites were identified by enzymatic 
digestion and site-directed mutagenesis studies. Cysteines and disulfide bonding pattern 
was analyzed by labeling the cysteine residues with different alkylating agents, enzymatic 
digestion with trypsin and chymotrypsin were performed and the bonding pattern was 
analyzed by Dr. Amy Ham at the Mass Spectrometry Research Center at Vanderbilt 
University. Some of these results are not complete, and further studies are necessary to 
get closer to understand the structure of hMPV F protein. 
 
3.2. Circular dichroism spectroscopy, surface plasmon resonance 
The far-UV protein spectrum (190-240 nm) measured by circular dichroism (CD) 
spectroscopy is sensitive to the overall secondary structure of the protein. It measures the 
absorbance difference by the sample between the right-handed and left-handed circularly 
polarized light. The method is sensitive to chirality and asymmetry around the 
chromophores in the sample. By spectral fitting one can estimate the percentage of α-
helix, β-sheet and random coil in the sample. The near-UV (240-340 nm) CD spectrum 
doesn’t have direct structural interpretation; it is sensitive to the local tertiary structure 
around aromatic residues and disulfide bonds. To characterize the hMPV F secondary 
structure we measured the far-UV absorbance of the sample by CD spectroscopy and 
analyzed the thermal stability of the protein. 
Surface plasmon resonance is a label-free technology to study biomolecular 
interactions and binding events. In BIAcore systems (BIAcore, Uppsala, Sweden), SPR is 
used to monitor interactions occurring in a biospecific surface, on a gold-coated sensor 
chip, where the surface is modified with a carboxymethylated dextran layer. The protein 
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(or other molecule) of interest is immobilized on the dextran surface and constant 
concentration of analyte(s) pass(es) over the sensor surface in a controlled, pulse-free 
flow. Binding events, association and dissociation rates are determined by detection of 
mass changes in the aqueous layer close to the sensor chip surface by measuring the 
changes in the refractive index. Since SPR provides quantitative information in real time 
on specificity of binding, kinetics and affinity, we used this method to study hMPV-
specific monoclonal antibody binding to purified hMPV F ectodomain. 
 
Materials and Methods 
CD spectroscopy. Purified hMPV F ectodomain stock was diluted to a 150 µg/ml 
concentration in phosphate buffered saline (PBS, Gibco) at pH=7.4, and CD spectra were 
collected on an Aviv 215 CD spectrophotometer over the wavelength range of 190 and 
260 nm at 25 °C with a resolution of 0.5 nm and bandwidth of 1.0 nm. For thermal 
stability the spectrum was measured at the same wavelength range with variable 
temperature control at every 5°C in the temperature range of from 25 to 100 °C. Sample 
was analyzed in a 300 µl stain-free quartz cuvette with 1 cm path length. 
SPR-BIAcore. The interaction between hMPV-specific monoclonal antibodies 
with hMPV F protein was monitored using surface plasmon resonance on a BIAcore 
2000. HMPV-specific human monoclonal Fab generated by combinatorial phage display 
technology was obtained from R. Anthony Williamson (Scripps Research Institute, La 
Jolla, CA); hamster monoclonal IgG was kindly provided by Nancy D. Ulbrandt 
(MedImmune, Gaithersburg, MD); Purified RSV F ectodomain and anti-RSV 
monoclonal antibody (Palivizumab) was obtained from Chris Keefer in Dr. Crowe’s lab 
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at Vanderbilt. Purified recombinant hMPV F and RSV F protein were diluted to 30 µg/ml 
in 10mM sodium acetate, pH 4.5, and covalently immobilized at 5 µl/min by amine 
coupling to the dextran matrix of a CM5 sensor chip (BIAcore) with an aimed RU 
density of 1200. Unreacted active ester groups were blocked with 1 M ethanolamine. For 
use as a reference, a blank surface, containing no protein, was prepared under identical 
immobilization conditions. Purified hMPV F antibodies and RSV-specific monoclonal 
antibody (Palivizumab), were injected over the immobilized hMPV F protein, RSV F 
protein, and reference cell surfaces at concentrations ranging from 5 to 500 nM in 
HBS/Tween 20 buffer (BIAcore). Antibody binding was measured at a flow rate of 30 
µl/min for 180 seconds and dissociation was monitored for an additional 360 seconds. 
Residual bound antibody was removed from the sensor chip by pulsing 50 mM HCl at 
100 µl/min for 30 seconds. Ka, kd, and KD was determined by globally fitting the 
binding curves to fit a 1:1 Langmuir binding model using the BIAevaluation software. 
 
 
Results 
The CD spectrum of purified F ectodomain indicated a predominant α-helical 
secondary structure. (Figure 22) This was not surprising, since it has been shown 
previously that the mixture of synthetic HR-1 and HR-2 peptides had similar curve with 
negative ellipticity (with double minima at 208 and 222 nm) characteristic of the α-
helical content. The protein concentration was 150 µg/ml; protein stock with higher 
concentration gave inconsistent results, probably because of protein aggregation. 
Although these data suggest that the protein is folded correctly and it contains the coiled 
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coil fusion core with dominant α-helices formed by HR-1 and HR-2 regions, it is still not 
known whether the protein is in its pre- or post-fusion state, in an intermediate form 
between the pre-and post-fusion state or in an artificial (but α-helical) conformation that 
was the result of our expression method and purification process. 
The thermal stability curve of the protein, however, did not give an exact melting 
temperature (Tm); the protein has been melted continuously in the temperature range of 
50-100 °C resulting an almost linear melting curve (data not shown). This was 
unexpected based on the previous HR-1/HR-2 synthetic peptide results, since they 
showed a very high, distinct melting point at about 90-95 °C. Our different melting data 
might be the result of the complexity of the whole protein, the instability of the trimers 
and the effects of the side chains, subunits, folding and storage buffer. 
 
SPR-BIAcore studies indicated that hMPV-specific Fab and hamster monoclonal 
IgG both bind to hMPV F ectodomain, but RSV-specific Palivizumab does not. Figure 
23 A shows the binding curve of anti-hMPV Fabs to hMPV F (The original 
measurements and fitted curves are shown in Appendix B). The binding curves at 
different antibody concentrations were fitted with a 1:1 Langmuir binding model. The 
BIAevaluation software determined the values of ka, kd and KD. In contrast, Figure 23 
A shows that Palivizumab, which is an anti-RSV monoclonal antibody did not bind to 
hMPV F at all, not even at 100 nM concentration. We tested the binding ability of 
Palivizumab to RSV-F (data not shown), and it exhibited strong, specific binding, so the 
lack of binding to hMPV F was the result of specificity and related to the quality of the 
antibody. 
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Figure 22. CD spectrum of hMPV F ectodomain shows predominant α-helical secondary 
structure. Spectrum was collected from a 150 µg/ml protein stock in PBS at 25 °C. 
 
 
 
Our anti-hMPV human monoclonal Fabs had specific affinity to hMPV F as 
indicated on Figure 23 B. It shows that the Fab at 50 nM concentration binds to hMPV F, 
but it has no affinity to RSV F protein. Values of ka, kd and KD were calculated by the 
fitted curves based on the association and dissociation rates. For the anti-hMPV human 
monoclonal Fab ka = 3.54e5 (1/s), kd = 3.48e-4 (1/s) and KD = 9.84e-10 (M). These values 
suggest a strong, specific antibody-antigen binding, and we got similar results for the 
full-length hamster monoclonal antibodies with a ka = 1.01e5, kd = 8.65e-4 and KD = 
8.56e-9 (M). For the human Fab we also found that it had significant neutralizing activity, 
with a neutralizing concentration of 1.1 µg/ml. So, this antibody specifically binds to a 
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neutralizing epitope on the protein surface. The hamster IgG did not have high 
neutralizing activity, but the strength of antibody-antigen binding was similar to that of 
the Fab. 
The antibodies were generated with different techniques and we received them 
from two distinct sources, and both showed specific binding to hMPV F ectodomain, 
which proves that our antigen retains at least some of the antigenic epitopes that are 
important in antigen-antibody recognition, binding and for some, virus neutralization. By 
detailed epitope mapping studies using the SPR-BIAcore method we could further test 
these antibodies (and others) in a pair-wise/competitive manner to see if they bind to the 
same epitope or to independent antigenic sites on the protein surface. This technique can 
also give some insight to the surface topology and steric interactions on the surface of the 
antigen, which comes from the secondary structure of the protein and the conformation of 
surface residues. 
The strong binding of these antibodies to hMPV F offers another approach for us 
to determine the protein structure. Since purification and crystallization of Fab fragments 
are relatively easy and substantial improvements in the methodologies helped to 
crystallize and determine Fab structures and also the structure of Fab-antigen complexes, 
we could use the strong binding of human Fabs to hMPV F to co-crystallize the antibody-
antigen complex. Fab might help stabilizing the crystals and we could get structural 
information not only about the protein itself, but the detailed structure of the epitope that 
serves as a place for specific, neutralizing antibody binding. 
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A) 
 
 
B) 
Figure 23. SPR-BIAcore kinetic analysis of anti-hMPV human monoclonal Fab binding 
to hMPV F ectodomain. A) HMPV-specific Fab (5-500 nM) binds to hMPV F 
ectodomain immobilized on CM5 sensor chip. 100 nM Palivizumab did not show 
binding. B) Anti-hMPV Fab (50 nM) binds specifically to hMPV F, but not to RSV F. 
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3.3. N-glycosylation, site-directed mutagenesis 
Glycosylation is a post-translational modification by carbohydrates that are 
attached to different amino acid side chains. O-glycosylated proteins have 
oligosaccharides at Thr and Ser residues, C-glycosylation means sugar chains are 
attached on Trp residues and N-glycosylated proteins are modified at the Asn residue of 
the consensus sequence Asn-Xaa-Ser/Thr (where Xaa can be any amino acid except 
Pro)40. The translation of mRNAs of membrane-bound or secretory proteins is initiated 
on membrane-bound ribosomes. The growing polypeptide chain is co-translationally 
translocated across the ER membrane via Sec61 translocon complex. During the process 
of translocation, the glycosylation sites on the nascent polypeptide chain are glycosylated 
in the lumen of the ER by a multi-subunit membrane protein complex called 
oligosaccharyl transferase (OT), so the processes of translocation and N-glycosylation are 
expected to be coupled events. N-glycans not only determine the folding, transport and 
translocation41 of the protein inside the cell, but they also modulate their immunogenicity 
and antigenic activity. Glycans can shield large portions of the protein surface, providing 
protection from proteases and masking epitopes. It has been shown that removal of 
carbohydrates from the protein surface can result a shift in the conformation of the 
polypeptide backbone, altering the recognition of immunogenic epitope42, 43. The role of 
N-glycosylation in protein function and immune recognition is not very well understood, 
but several studies have been performed to investigate N-glycans in paramyxoviruses42-45 
and in case of other viruses46. 
The NetNGlyc 1.0 algorithm predicted that hMPV fusion (F) protein has three 
potential N-glycosylation sites at the positions of N57, N172 and N353. These 
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asparagines represent conserved residues in all of the hMPV isolates worldwide. To 
determine N-glycans that are attached to the asparagine residues at these positions we 
used enzymatic digestion with N-glycosidase F and site-directed mutagenesis to modify 
the asparagine residues to glutamine. Single, double and triple mutants were generated by 
changing N to Q either individually or in combinations. All of the mutated plasmid 
constructs were successfully transfected in 293-F mammalian suspension cell line and 
mutated proteins were expressed in the culture medium. 
 
Materials and Methods 
Site-directed mutagenesis of N-glycosylation sites. N-glycosylation mutants were 
generated by replacing asparagine (N) residues with glutamine (Q) at positions N57, 
N172 and N353. Single, double and triple mutants were made by changing only one 
(N57Q, N172Q, N353Q), two (N57/172Q, N57/353Q, N172/353Q) or all three 
(N57/172/353Q) N-glycosylation sites, respectively. Combinations of two and three sites 
were performed in a stepwise manner. QuikChange Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA) was used to make point mutations at potential glycosylation 
sites. Sense and antisense PCR primer pairs designed for mutations are listed in Table 2. 
Triplet AAC encoding for asparagine was changed for CAA, which encodes for 
glutamine in the codon-optimized sequence (changes underlined in the primer 
sequences). All mutated plasmid constructs were sequenced by the Vanderbilt DNA 
Sequencing Facility to confirm nucleotide changes. 
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Table 2. PCR primers designed to generate N-glycosylation mutants. 
N57Q   (sense) 5’-GTGGGCGACGTGGAGCAACTGACCTGCAGCGAC-3’ 
       (antisense) 5’- GTCGCTGCAGGTCAGTTGCTCCACGTCGCCCAC-3’ 
N172Q (sense) 5’-AAGGACTTCGTGAGCAAGCAACTGACCAGAGCCATCAAC-3’ 
       (antisense) 5’- GTTGATGGCTCTGGTCAGTTGCTTGCTCACGAAGTCCTT-3’ 
N353Q (sense) 5’- GTGCAACATCCAAATCAGCACAACCAACTACCCC-3’ 
       (antisense) 5’- GGGGTAGTTGGTTGTGCTGATTTGGATGTTGCAC-3’ 
 
 
HMPV F ectodomain and the N-glycosylation site-mutated protein expression in 
transfected mammalian cells. The pcDNA3.1-F∆TM recombinant plasmid and mutated 
plasmid constructs were transfected into suspension 293-F cells as recommended by the 
manufacturer (Freestyle 293 Expression System, Invitrogen). 1x107 number of cells and 
30 µg plasmid were used for each transfection, so the rate of protein expression is 
comparable. Four days post-transfection cells were centrifuged for 5 min at 100 x g at 
room temperature, supernatant containing the expressed, soluble protein was removed for 
purification and further analysis.  
Gel electrophoresis, Coomassie staining and Western blot. Procedure was 
followed as written in 2.2 in Chapter II. 
Deglycosylation with N-glycosidase F. To determine the N-glycans that are 
attached to asparagine residues at the potential glycosylation sites protein was treated 
with N-glycosidase F (Calbiochem, San Diego, CA). 30 µl of purified protein was heat 
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denatured at 95 °C for 10 min in denaturation buffer (Calbiochem). After cooling 2.5 µl 
of NP-40 and 2 µl of N-glycosidase F were added and protein was digested at 37 °C 
overnight. Migration of protein bands was analyzed on SDS-PAGE gels. 
Staining cells on Bartels identification slides. 293-F and transfected cells were 
centrifuged for 15 seconds, supernatant was removed and cells were resuspended in PBS. 
One drop of suspended cells were placed on the wells of identification slides, dried and 
fixed in acetone at -20°C. Slide was placed in humidified chamber and stained with anti-
hMPV polyclonal guinea pig serum at 1:200 dilution in phosphate buffered saline with 
1% Tween (PBS-T) for 30 min. Slides were incubated in PBS-T for 6 min in a Copeland 
jar, then dried and stained for 30 min with secondary goat anti-guinea pig antibodies 
conjugated with Alexa Fluor 568. Washing step in PBS-T was repeated and the slide was 
finally washed with water. Stained cells were examined in a Nikon Diaphot inverted 
microscope. 
 
Results 
We digested the purified hMPV FΔTM with N-glycosidase F in order to see if the 
expressed, purified protein contains carbohydrate chains at the potential N-glycosylation 
sites. Digested protein was loaded on 4-12% SDS gel and run under denaturing, non-
reducing conditions (for enzymatic digest the protein already had to be in denatured form, 
so we couldn’t use native conditions). Coomassie blue stained gel, Western blots with 
anti-polyHistidine mouse monoclonal primary antibodies and with anti-hMPV polyclonal 
guinea pig serum were used to analyze protein digestion. Figure 24 A, B shows the 
Western blot results following N-glycosidase F digestion of FΔTM. 
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 A) 
 
 
 
B) 
Figure 24. Western blot of hMPV FΔTM digested with N-glycosidase F. A) FΔTM is 
digested with increasing amount of N-glycosidase F. Lane 1: MW marker, lane 2: 
undigested FΔTM (bands corresponding to possible dimeric and trimeric forms of F are 
visible), lanes 3 and 4: FΔTM digested with 6 µl and 10 µl of N-glycosidase F, 
respectively. B) Mass difference between the fully aglycosylated and undigested protein. 
Lane 1: MW marker, lane 2: undigested FΔTM at 0.5 mg/ml concentration, lanes 3 and 4: 
fully digested, aglycosylated and undigested, diluted protein bands. Note that protein 
stored in PBS for 1-2 weeks undergoes degradation and looses some of the carbohydrate 
chains, as can be seen in lane 2 and 4. Anti-polyHistidine mouse monoclonal antibodies 
were used as primary antibody for Western blot. 
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Although Western blots of digested FΔTM proved that the protein is glycosylated 
and we could see the mass difference between the aglycosylated and the undigested 
forms, enzymatic analysis did not give us information about the glycosylation of the 
individual N-glycosylation sites and the lengths of the carbohydrate chains attached to the 
asparagine residues. Expression of mutated F proteins helped to answer these questions. 
Plasmids containing N/Q single, double or triple mutations at the positions of 
N57, N172 and N353 were successfully transfected into 293-F mammalian cells, 
similarly to the wild type F protein. As a positive control, the original plasmid for FΔTM 
was used for transfection and protein expression and untransfected cells were the 
negative control. We used the same amount of plasmid, cell number, and conditions for 
each transfection. We analyzed the transfected cell lysates as well as the supernatant by 
gel electrophoresis and immunoblots for protein expression. Figure 25 shows Western 
blot results of the supernatant removed from cells transfected with the original FΔTM and 
the mutated plasmids. All mutated proteins were successfully expressed in the culture 
media except double mutant N172/353Q and the triple mutant N57/172/353. This was a 
surprise, although not totally unexpected, since we knew from previous reports that 
mutations at N-glycosylation sites of other paramyxovirus fusion proteins effect protein 
transport and expression. Both N172 and N353 residues are in the F1 subunit, so these 
findings might suggest that for correct protein folding and expression at least one of these 
glycosylation sites has to be glycosylated. Since both anti-polyHistidine and anti-hMPV 
antibodies recognized the other mutants, and they don’t bind to the same epitope on the 
protein, lack of detection of these two mutants might be the result of failed protein 
expression. Interestingly, the analysis of cells lysates showed no difference for the 
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mutants, protein seemed to be present in the cell lysate by Western blots (data not 
shown). We also fixed and stained the transfected cells (along with untransfected ones as 
a negative control) on a slide to show the presence of mutated proteins inside the cell by 
immunofluorescence. All mutated samples were positive for staining with anti-hMPV 
polyclonal serum compared to the untransfected control, in which we detected only 
background fluorescence. The presence of the mutated proteins in the cytoplasm/cellular 
compartments suggests that protein expression failed somewhere at the transport-folding-
secretion steps, since transcription and translation seem to be unaffected by the 
mutations. However, to prove that transcription is not affected by the mutations, studies 
using RT-PCR with hMPV F-specific primers would be helpful. In addition, further 
experiments can be designed to analyze the effects of mutations on protein transport 
inside the cell, protein translocation in the cellular compartments, folding and 
modifications of the nascent polypeptide chains and expression of the mutated proteins. 
Based on the Western blot results on Figure 25 one can also notice that the rate of 
glycosylation and the lengths of the carbohydrate chains are very similar at the individual 
sites. However, it has to be mentioned that proteins expressed by different cell lines may 
display completely different arrays of carbohydrates and the site heterogeneity and 
occupancy might also be affected. Selective labeling, partial digestion of carbohydrates 
or mass spectrometry analysis could give a more detailed picture about the 
oligosaccharide chains attached to the individual sites. 
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Figure 25. Western blots of FΔTM and mutated proteins. Lane 1: MW marker, 2: FΔTM, 
3: N57Q, 4: N172Q, 5: N353Q, 6:N57/172Q, 7: N57/353Q, 8: (N172/353Q, not 
expressed in the medium), 9: (N57/172/353, not expressed in the medium). For the upper 
blot the primary antibody was anti-hMPV polyclonal guinea pig serum, the lower was 
done with anti-polyHistidine monoclonal antibodies. 
 
 
3.4. Disulfide-mapping, computer models 
To solve the structure of hMPV F protein without crystallizing it is a challenging 
task. There are many tools that one can use to map and characterize the secondary 
structure of subunits, antigenic sites and important epitopes. Computer models can also 
help by using the sequence homology, structural and chemical analogy between 
conserved residues of different viruses. Another useful approach is analytical proteomics. 
Protein identification is built around the fact that most peptide sequences of 
approximately six or more amino acids are largely unique in the proteome of an 
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organism. So, if we can obtain the sequence of the peptide or accurately measure its 
mass, we can identify the protein it came from47. 
The idea behind our disulfide-mapping experiment is, that if we are able identify 
and map the disulfide-bonding pattern in hMPV F, we can build a computer model based 
on previously reported paramyxovirus crystal structures (e.g. NDV, hPIV-3) and modify 
it according to the actual disulfide bond arrangement. With this approach we could 
simulate the secondary structure of hMPV F without crystallizing the protein itself. 
Disulfide mapping by mass spectrometry is a difficult process, especially for large 
proteins. The greater the mass, the larger the absolute magnitude of error. Disulfide 
mapping is hard, but not only because of the size of the polypeptide chain, but also 
because of the folding and secondary structure of the native protein. We want to map the 
intact, native protein, without disturbing the original bonding pattern, but some residues 
might be inside the secondary structure hidden from alkylating and reducing agents and 
enzymes. Besides the protein secondary structure, post-translational modifications (e.g. 
cleavage, glycosylation) further complicate assignments based on mass. 
Another approach that could be used to map the disulfide-bonding pattern instead 
of peptide analysis is site-directed mutagenesis experiment. Similar experiments were 
described previously, such as the mutation of cysteine residues in RSV F protein48. 
However, as we saw earlier in case of hMPV F N-glycosylation mutants, changing 
important residues in the wild type protein might have effect on protein transport, folding 
and expression, and some of the mutants could not be expressed at all. 
So, we went on with the disulfide mapping process by labeling the cysteine 
residues with alkylating agents under non-reducing and reducing conditions to find free, 
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unbound sulfhydryls and disulfide-bonded cysteines. Peptide fragments were generated 
by enzymatic digestions. We needed peptide fragments, possibly between 6 to 20 amino 
acid residues, for ideal MS analysis. In order to map the entire sequence with short (but 
not too short) peptides, we had to use two different proteases: trypsin and chymotrypsin. 
These widely used enzymes have good activity both in solution and ‘in gel’ digestion. 
Trypsin has a characteristic autolysis fragmentation, which appears as by-product of 
tryptic-digestion protocols and it can serve as a calibration point. Trypsin cleaves proteins 
after lysine and arginine residues (cannot be followed by proline) and chymotrypsin cuts 
after tryptophane, tyrosine and phenylalanine residues (unless followed by proline). 
 
Materials and Methods 
Protein sample preparation for mass spec analysis, buffers, reagents. Protein 
stock with ∼20 µM concentration was prepared, filtered through a 30 kDa MC 
regenerated cellulose filter (Millipore) and buffer was exchanged with 50-100 mM 
ammonium bicarbonate buffer, pH 8.0 To reduce disulfide bonds in the protein 1/10 
volume of 50mM dithiothreitol (DTT) was added to the sample and incubated for 20 
minutes at 60°C. To label free sulfhydryl groups and the reduced cysteines prior and after 
reduction by DTT alkylating agents, such as N-ethylmaleimide (NEM) and 
iodoacetamide (IAM) were used, respectively. Trypsin and chymotrypsin digest of 
reduced and unreduced sample was performed, as previously described by Manza et al49. 
LC-MS analysis of digested hMPV F ectodomain. LC-MS analysis of the resulting 
peptides was performed using a ThermoFinnigan LTQ ion trap mass spectrometer 
equipped with a Thermo MicroAS autosampler and Thermo Surveyor HPLC pump, 
 77
Nanospray source, and Xcalibur 1.4 instrument control.  The peptides were separated on 
a packed capillary tip, 100 μm x 11 cm, with C18 resin (Jupiter C18, 5 micron, 300 
angstrom, Phenomonex, Torrance, CA) using an inline solid phase extraction column that 
was 100μm x 6cm packed with the same C18 resin (using a frit generated with from 
liquid silicate Kasil 150) similar to that previously described by Licklider et al.51, except 
the flow from the HPLC pump was split prior to the injection valve.  The flow rate during 
the solid phase extraction phase of the gradient was 1 μL/min and during the separation 
phase was 700 nl/min.  Mobile phase A was 0.1% formic acid, mobile phase B was 
acetonitrile with 0.1% formic acid.  A 95 min gradient was performed with a 15 min 
washing period (100 % A for the first 10 min followed by a gradient to 98% A at 15 min) 
to allow for solid phase extraction and removal on any residual salts.  After the initial 
washing period, a 60 minute gradient was performed where the first 35 min was perform 
a slow, linear gradient from 98% A to 75 % A, followed by a faster gradient to 10 % A at 
65 min and an isocratic phase at 10 % A to 75 min. The MS/MS spectra of the peptides 
was performed using data-dependent scanning in which one full MS spectra was followed 
by 3 MS/MS spectra. 
Data analysis. The data were searched with the Sequest algorithm using a human 
database created from the Uniref100. Protein matches were preliminarily filtered using 
the following criteria: if the charge state of the peptide is 1, the xcorr is greater than or 
equal to 1, the RSp is less than or equal to 5, and the Sp is greater than or equal to 350. If 
the charge state is 2, the xcorr is greater than or equal to 1.8, the RSp is less than or equal 
to 5, and the Sp is greater than or equal to 350.  If the charge state is 3, the xcorr is 
greater than or equal to 2.5, the RSp is less than or equal to 5, and the Sp is greater than 
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or equal to 350. Once filtered based on these scores, all protein matches that had less than 
two peptide matches were eliminated from the search. Sample preparation, enzymatic 
digest and data analysis were performed in the Proteomics Laboratory within the Mass 
Spectrometry Research Center at Vanderbilt University under the supervision of Dr. Amy 
Ham. 
 
Results 
Both the hMPV F protein and the purified ectodomain have 14 cysteines (no Cys 
in the transmembrane domain and cytoplasmic tail), so in disulfide mapping experiments 
we could use the purified ectodomain in order to map all the disulfide bonds and cysteine 
residues that are present in the native protein. The protein was labeled by NEM alkylating 
agent prior reduction and digest to find the free sulfhydryl groups in the construct. Our 
results indicate that there are no free cysteines in the protein (although residues that were 
not accessible to alkylating agents prior reduction and digest because of protein folding 
and 3D structure would also fall in this category), so presumably all the cysteine residues 
that we found in the sequence, participate in disulfide bond formation. 
Tryptic and chymotryptic digests were used to cover the almost the entire 
sequence of FΔTM and to get shorter overlapping peptides, since 6-20 amino acid-long 
peptide fragments are ideal for MS analysis. With the two-enzyme digestion we couldn’t 
find one cysteine (Cys 60). All the other 13 cysteines are covered and identified after 
reduction and the enzymatic digests. Figure 26 shows the coverage map following 
cleavage by trypsin and/or chymotrypsin. Overlapping peptides were identified both by 
tryptic and chymotryptic digests. 
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Figure 26. Coverage map of FΔTM digested with trypsin and chymotrypsin. Fragments 
identified by chymotryptic digestion are in red. Fragments identified by tryptic digestion 
are underlined. Cys60 (blue) is not covered by the peptides that were identified. 
 
Further mass spectrometry analyses will determine the actual bonding pattern 
among cysteine residues. Once we know that we will use this information to modify our 
existing computer model. Previously, Scott Miller at Vanderbilt University generated a 
computational model of the hMPV F fusion core39. He examined the available hexameric 
crystal structures for similarity with hMPV F heptad repeat regions, and obtained a 
reasonably good homology model based on the sequence identity of hMPV F with the 
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RSV F fusion core (50% sequence homology in HR-1 and 35% I HR-2). The overall 
energy and probability function density values were calculated for each model to isolate 
the most stable final model (Figure 27). Overall, the hMPV fusion core model was 
consistent with other hexameric cores found in type I viral fusion proteins. Details about 
the cysteine-bonding pattern will make further refinements in this computer model and 
take us closer to the real protein structure. 
 
 
Figure 27. Hexameric fusion core of hMPV F model. The sequence of RSV F fusion 
core crystal was subjected to a strong local alignment with hMPV F sequence to 
determine appropriate homology sequences for the hMPV F fusion core model. (Left) 
The surface of HR-1 trimeric stalk (red: solvent exposed, blue: hydrophilic, green: 
hydrophobic) with the HR-s (purple ribbon) filling the hydrophobic grooves. (Right) 
Axial view of the hexameric coiled coil. Adapted from Miller39. 
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3.5. Discussion 
The results of our structural studies on purified hMPV ectodomain further proved 
that we successfully generated a recombinant protein by using mammalian expression 
system that was secreted in a soluble state and forms trimers under native conditions. CD 
spectroscopy studies showed that the protein retains a dominant α-helical secondary 
structure. Our results are consistent with the data of other fusion protein hexameric cores 
found in the literature29, 31, 52 and also with our synthetic peptide studies39, although it is 
the subject of further experiments to find out that this conformation belongs to the pre- or 
post-fusion form or an intermediate state35. According to the fusion model based on 
hPIV-3 and SV5 F crystal structure, after cellular docking the cleavage activated pre-
fusion F protein undergoes a conformation change via a transient pre-hairpin structure, 
where the fusion peptide gets exposed toward the target membrane and inserts into it. 
Another series of conformational changes refolds the HR-2 region into an α-helical 
structure and the formation of the hexameric fusion core in the post-fusion state pulls the 
target membrane close to the viral membrane, resulting fusion35. In case of hMPV F the 
dominant α-helical structure can be either the pre- or the post-fusion state, although the 
fact that adding synthetic HR-1 or HR-2 peptides to the F ectodomain did not cause 
changes in the secondary structure (data not shown) suggests the post-fusion state. 
If we talk about the fusion mechanism here, we have to mention the unusual 
behavior of synthetic hMPV HR-1 peptides in membrane fusion inhibition assays. The 
postulated mechanism for fusion inhibition by synthetic peptides is that binding of the 
individual HR-2 peptides to the hydrophobic grooves presented on the surface of HR-1 
helical trimers in the pre-fusion or pre-hairpin intermediate inhibits fusion by blocking 
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the surface from the native HR-2 regions of the protein, so conformation change cannot 
occur. In case of hMPV F, while HR-2 peptides prevented fusion as predicted by the 
literature, HR-1 peptides inhibited fusion at least 1000 times more effectively than the 
previously reported HR-1 peptides from other paramyxoviruses. These findings might 
suggest that hMPV F protein has different structural properties than other 
paramyxoviruses or subtle, but distinct differences in the fusion core structure that cause 
different behavior in fusion inhibition. Although the overall protein structure is probably 
very similar to other paramyxovirus fusion proteins, we have to be critical in the fine 
details, because these might have major effects on protein function and its role in the 
fusion mechanism. Further structural studies on hMPV F probably will focus on the 
hexameric fusion core and give detailed information about the secondary structure of this 
important protein region, so it will help us to understand better the structural-functional 
connections. 
Experiments using SPR methods confirmed that our recombinant protein 
construct presents at least some of the major antigenic epitopes on its surface that are 
recognized by hMPV-specific monoclonal antibodies and are important in viral 
neutralization. These findings suggest that the recombinant hMPV F ectodomain 
possesses native conformation. The fact that some neutralizing (and non-neutralizing) 
antibodies bind very strongly to the recombinant hMPV F gives new possibilities for 
epitope mapping studies, crystallization of the protein and also vaccine development. 
With the mammalian expression system and codon-optimization strategy we were 
able to express a protein that is cleaved and glycosylated at all three potential N-
glycosylation sites. We also showed that glycosylation of the F1 subunit is necessary for 
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correct protein transport, folding and expression. Changing the glycosylation sites by 
mutagenesis had an effect on protein translocation and folding, since some of the mutated 
proteins containing changes in the F1 glycosylation sites could not be expressed in the 
culture medium. It would be interesting to study these mutagenesis constructs (e.g. in in 
vivo animal models) in order to determine the effect of glycosylation on immunogenicity 
and antigenic activity. Furthermore, enzymatic deglycosylation of the expressed protein 
might help in successful crystallization of the ectodomain, although glycosylation has 
important role in the formation of the correct secondary and tertiary structure. 
We also proved that all fourteen cysteine residues that are present in the 
recombinant hMPV F ectodomain form disulfide bonds. The disulfide-bonding pattern 
will be further analyzed with proteomics methods and mass spectrometry analysis. Once 
we determine the actual bonding pattern in the sequence, we will be able to modify our 
computer model that was generated based on the known crystal structures of other 
paramyxovirus fusion cores. 
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CHAPTER IV 
 
F PROTEIN BINDING TO RGD-SPECIFIC ADHESION MOLECULES 
 
4.1. Introduction 
Integrins are structurally, immunochemically and functionally related cell-surface 
heterodimeric receptors that are widely expressed on metazoan cell membranes and 
integrate the extracellular matrix with the intracellular cytoskeleton to mediate cell 
migration, and adhesion53. They activate intracellular signaling and play crucial role in 
development, immune responses, leukocyte trafficking and hemostasis54, 55. Integrins are 
heterodimeric molecules, comprising 18 α and 8 β subunits that are currently known to 
assemble into 24 distinct integrins. These subunits interact non-covalently in a restricted 
manner. The diversity of integrins is expanded further by alternative splicing, post-
translational modifications and interactions with other cell-surface and intracellular 
molecules53. 
The members of the integrin family recognize multiple ligands. The list of such 
ligands includes a large numbers of extracellular matrix proteins (bone matrix proteins, 
collagens, fibronectins, fibrinogen, laminins, thrombospondins, vitronectins and von 
Willebrand factor), which reflects the primary function of integrins in cell adhesion to 
extracellular matrices. Integrins also mediate cell-cell interactions and many 
microorganisms utilize integrins to gain entry into the host cells. A group of integrins has 
RGD recognition specificity meaning that these types of integrins recognize Arg-Gly-Asp 
(RGD)-containing ligands. RGD sequence was originally identified as the sequence in 
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fibronectin that engages the fibronectin receptor, α5β1, but now it’s known that it serves 
as a recognition motif in multiple ligands for several different integrins. A number of 
viruses have been shown to utilize RGD-recognizing integrins as receptors or co-
receptors, including echovirus, adenovirus, human parechovirus, foot-and-mouth disease 
virus, rotavirus, hantavirus, West Nile virus, human herpes virus-8 and reovirus56-61. 
Virus binding to these integrin receptors can be inhibited with RGD containing peptides 
or function blocking anti-integrin antibodies. 
Each integrin heterodimer contains 3-5 divalent cation (Ca2+, Mg2+ or Mn2+) 
binding sites and these bound cations can act as effectors, promoting ligand binding; as 
antagonists, inhibiting ligand binding; and as selectors, changing the ligand binding 
specificity53. Thus, ligand binding can be blocked using chelating agents that bind 
divalent cations, such as EDTA. 
Integrin binding to viral proteins has been shown to mediate attachment or 
internalization, as well as intracellular signaling cascades. Virus-integrin binding triggers 
activation of focal adhesion kinase (FAK) in cells infected with HHV-8 and West Nile 
virus. In case of HHV-8 it has been reported that binding of recombinant viral 
glycoprotein gB alone activated FAK and paxillin. So, virus binding to RGD-specific 
integrins can be monitored by the detection of phosphorylation of FAK in the infected 
cell. 
Sequence analysis of the F genes from over 78 clinical isolates collected over a 
20-year period at Vanderbilt University along with the full-length F gene sequences 
deposited in Genbank showed that there is an Arg-Gly-Asp (RGD) motif that is 
absolutely conserved in all hMPV F sequences. This motif is unique to hMPV F among 
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human paramyxovirus fusion protein and it is in a region predicted to be surface exposed 
by antigenic and hydrophilicity plots. These findings let us to further investigate the 
possibility that integrin binding might be a function of hMPV F protein. Confirming that 
hMPV F binds to RGD-specific receptors will help to elucidate mechanism of 
pathogenesis, understand viral-cell receptor interactions and lead to develop targeted 
antivirals to treat severe hMPV disease in the high-risk population, such as infants, young 
children, elderly and immunocompromized people. 
We identified permissive and poorly permissive cell lines for hMPV infection and 
probably found that there is a correlation between permissivity for hMPV and the types 
of surface expressed integrins. LLC-MK2 cells, a monkey renal epithelial cell line, are 
equally permissive for RSV and hMPV ad both viruses grow to equivalent titers of 106 
pfu/ml in hMPV growth medium. CHO cells (Chinese hamster ovary cells), however, are 
poorly permissive for hMPV infection, with yield of approximately 20% of that of LLC-
MK2 cells. LLC-MK2 cells have several RGD-binding integrin expressed on the surface: 
αv, α5, β1, β3, β5, while CHO cells express only some of the α5 and β3 integrins. To 
show the correlation between integrin surface expression and hMPV infectivity we tried 
to block hMPV infection in LLC-MK2 cells with EDTA, which is a chelating reagent 
that binds divalent cations, linear RGD-containing oligopeptides and function blocking 
anti-integrin antibodies. To further confirm this correlation we planed loss-of-function 
studies on LLC cells and gain-of function permissivity experiments with CHO cells to 
specifically prove hMPV F binding to certain types of RGD-binding integrins.  
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4.2. Materials and Methods 
Fluorescent-focus assay of hMPV infectivity. LLC-MK2 cell monolayers were 
pre-incubated with the putative inhibitor for 60 minutes, virus was adsorbed at 4 °C (at 
which cell entry does not occur) for 60 min and cells were incubated at 37 °C for one 
hour to allow membrane fusion and virus entry. Virus inoculum was removed by washing 
the monolayer with PBS three times. Cells were incubated for 24 hours (a single cycle for 
viral replication), fixed and stained by indirect immunofluorescence for hMPV or RSV. 
Infectious foci were counted in three replicate experiments. Infectivity is expressed as the 
percentage of fluorescent foci compared to control wells inoculated with virus alone in 
the absence of any inhibitor. 
Detection of integrin receptors by flow cytometry. Human anti-αV integrin 
antibodies (MAB1219, mouse IgG1) were purchased from R&D Systems, human anti-β1 
integrin antibodies (AIIB2, rat IgG) from DSHB at University of Iowa and anti-β3 
integrin antibodies (MAB1957Z, mouse IgM) from Chemicon. LLC-MK2 and CHO cells 
were detached from culture plates by scraping and centrifuged at 2600 rpm for 5 min. 
Culture media was removed and 2-3x105/ml cells were resuspended in 1.2 ml of staining 
buffer (PBS with 1%FBS, 1% BSA and 1% goat serum). Cells were centrifuged and 
washed with staining buffer one more time then resuspended in 200 µl staining buffer 
containing anti-αV or -β1 or -β3 integrin primary antibodies. Cells were incubated for 30 
min at 4 °C then centrifuged at 2600 rpm for 5 minutes, staining medium was removed 
and cells were resuspended in 1.2 ml staining buffer. Cells were washed one more time 
and resuspended in 200 µl staining buffer with FITC-conjugated goat anti-mouse or goat 
anti-rat IgG secondary antibodies (1:500 dilution). Cells were stained for 30 min at 4 °C, 
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centrifuged and resuspended in 1 ml staining buffer. Flow cytometric analysis was 
performed with a BD LSR II instrument at the VUMC Flow Cytometry Core at 
Vanderbilt University. 
Integrin plasmid constructs. Plasmids with cDNA encoding for human integrins 
were kindly provided by Melissa Maginnis in Dr. Dermody’s lab at Vanderbilt 
University.  A cDNA encoding human integrin αv cloned into the BamHI and XbaI site 
of pcDNA-1neo was excised by digestion and subcloned into pcDNA3.1+ (Invitrogen) 
using complementary restriction enzyme sites. A cDNA encoding human β1 integrin 
cloned into the EcoRI and XhoI sites of pBluescript SK- was obtained from the ATCC 
(Manassas, VA) and was excised by digestion and subcloned into complementary 
restriction enzyme sites of pcDNA3.1+. A cDNA encoding human integrin β3 cloned 
into the XbaI site of pcDNA-1neo was excised by digestion subcloned into the XbaI site 
of pcDNA3.1. A cDNA encoding β5 cloned into the EcoRI site of pcDNA-1neo was 
excised by digestion and subcloned into the EcoRI site of pcDNA3.1+. Successful 
cloning was confirmed by automated sequencing at Vanderbilt DNA Sequencing Facility. 
Transfection of integrin cDNA. One day before transfection CHO cells were 
seeded in Ham’s F12K growth medium supplemented with 5% fetal bovine serum on 24-
well plates, so they were 80-90% confluent on the day of transfection. Cells were 
transfected with human αV and β1 integrin cDNA in pcDNA 3.1+ expression vector by 
using 1 µg integrin cDNA and 1 µl TransFectin Lipid Reagent (Bio-Rad)/well. 
Transfection protocol was followed as recommended by the manufacturer. Cells were 
incubated 24-48 h at 37 °C and 5% CO2 before further analyses. 
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HMPV F protein binding assay. Purified hMPV F ectodomain was prepared as 
described previously (hMPV vaccine paper). LLC-MK2 and CHO cells were detached 
from culture plate and pelleted by centrifugation. 2-3x105 cells/ml were resuspended in 
1.2 ml staining buffer (PBS with 1% FBS, 1%BSA and 1% goat serum) in Eppendorf 
tubes. Cells were pelleted and washed again with staining buffer then resuspended in 200 
µl staining buffer with 10 µg/tube of purified hMPV F ectodomain and incubated for 1 h 
at 4 °C. Cells were centrifuged, buffer was removed and after washing cells were 
incubated with 200 µl staining buffer with anti-hMPV polyclonal guinea pig serum for 30 
min at 4 °C. Cells were pelleted, washed twice and stained with 200 µl staining buffer 
with Alexa Fluor 568-conjugated goat anti-guinea pig IgG secondary antibodies 
(Molecular Probes) for 30 min at 4 °C. After washing cells were resuspended in staining 
buffer and analyzed by flow cytometry. 
Integrin gene knockdown with siRNA. LLC-MK2 cells were plated on 24-well 
plates in Opti-MEM growth medium supplemented with 2% fetal bovine serum. Cells 
were 90% confluent on the day of siRNA transfection. Human αV and β1 integrin 
siRNAs were ordered from Qiagen and reconstituted in our laboratory as recommended 
by the manufacturer. Cells were transfected with 5-10 nM siRNA and 3 µl HiPerFect 
Reagent (Qiagen) per well. 48 h post-transfection cells were harvested by scraping, 
integrin mRNA was quantitated by RT-PCR and integrin surface expression was 
analyzed by flow cytometry. 
HMPV binding and infectivity assay. LLC cells in 48-well plates were washed 
twice with PBS. To three wells of 48-well plate a serial dilution of EDTA from 2.5 mM 
to 300 nM concentrations was added, this served as a positive control for the infectivity 
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assay. The appropriate dilutions of integrin antibodies were added to triplicate wells of 
the plate. To the virus control well 75 µl of 0% OptiMEM medium was added. Cells were 
incubated for 90 min at 37°C in a humidified incubator with 5% CO2, then for 30 min at 
4°C. 10 µl hMPV diluted to give approx. 60 virus particle/10 µl was added to each well. 
Plates were incubated for 60 min at RT, then for 60 min at 37°C with 5% CO2. Cells were 
washed with PBS twice and 0.5 ml OptiMEM medium supplemented with 2% FBS was 
added to the wells. Cells were incubated for 24 h at 37°C with 5% CO2. Cells were fixed 
with formalin and stained with anti-hMPV polyclonal guinea pig serum and with HRP-
conjugated goat anti-guinea pig IgG at 1:1000 dilution in blotto. Plates were rinsed with 
water and 100 µl of TrueBlue peroxidase substrate was added to each plate and incubated 
for 10 min at RT to develop color. Plates were rinsed with water, dried and stained cells 
were counted. 
4.3. Results 
Blocking hMPV infectivity in LLC-MK2 cells. We tested the effects of EDTA, 
RGD-containing peptides and function blocking anti-integrin antibodies on hMPV 
infectivity in LLC-MK2 cells. Integrin function is divalent cation-dependent and the 
binding of other viruses to RGD-binding integrins can be blocked by the presence of the 
divalent cation chelator EDTA. We tested the ability of EDTA to inhibit hMPV binding 
and infection of cells in vitro in a quantitative fluorescent-focus based assay we 
developed. We included RSV as a control virus, because it is a closely related 
paramyxovirus, but RSV F protein lacks the RGD motif. We performed in vitro 
infectivity assays on LLC-MK2 cells with hMPV and RSV, in the presence or absence of 
increasing (0.3 mM - 2.5 mM) EDTA concentrations. These experiments demonstrated 
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that there is a titratable concentration-dependent effect of EDTA on hMPV infectivity in 
LLC cells, with complete inhibition at EDTA concentrations above 2.5 mM (Figure 28). 
EDTA had no effect on RSV infectivity at any concentration. These differences were 
highly statistically significant and these data suggest that EDTA exerts a specific 
inhibitory effect on hMPV and support a role for integrins in hMPV infection. 
 
 
Figure 28. Effect of decreasing EDTA concentration on infectivity of hMPV and RSV. 
Mean percent infectivity was calculated as percentage of fluorescent foci compared to 
control wells inoculated with virus alone in the absence of any inhibitor. Data represents 
three separate experiments, and means were compared with student’s t test, 2-tailed 
assuming unequal variance. White bars are RSV infected controls, black bars represent 
hMPV infected cells. 
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We also tested specific oligopeptide (GRGDSP) inhibitors as well as a control 
(GRGESP) peptide in the same quantitative assay. Increasing concentrations of GRGDSP 
had increasing inhibitory effect on hMPV infectivity (Figure 29), while the control 
GRGESP peptide had no effect (data not shown). Neither peptide exhibited any 
inhibitory effect on RSV, suggesting a specific effect on RGD-binding by hMPV. The 
inhibitory effect of linear GRGDSP peptides was modest, consistent with the results 
reported by other investigators in similar studies of virus-integrin binding. 
 
 
Figure 29. Effect of decreasing GRGDSP linear peptide concentration on hMPV and 
RSV infectivity. White bars are RSV infected controls, black bars represent hMPV 
infected cells.  
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Previously, it has been reported that function-blocking monoclonal antibodies 
directed against specific RGD-binding integrins inhibited viral infectivity. We performed 
experiments using commercially available anti-integrin monoclonal antibodies that were 
previously determined to possess function-blocking activity by the supplier or other 
investigators. Cell monolayers were pre-incubated with the antibodies, then infected with 
hMPV or RSV by the same method described in the experiments with EDTA or RGD-
containing peptides. We found that antibodies against αv and β1 integrin exhibited the 
greatest inhibition of hMPV infectivity, while no inhibition of RSV (Figure 30). Anti-αv 
and anti-β1 antibodies combined together showed even greater inhibition than either 
alone, suggesting synergy for the combination. While anti-β3 antibodies showed modest 
effect, anti-αvβ3 and anti-αv alone had a greater inhibition, which suggests that αv is 
more important for infectivity. Antibodies against α5 and β5 integrins had no effect (data 
not shown). All of these data suggest that αvβ1 heterodimers might be required for 
hMPV infection and further support the hypothesis that this interaction occurs at the site 
of integrin expression on the cells surface, where viral attachment and entry occur. 
hMPV F binding to LLC-MK2 cells. To test whether or not our purified hMPV F 
ectodomain (which also contains the RGD-motif) binds to αvβ1 integrins, LLC-MK2 
cells were incubated with hMPV FΔTM at 4 °C for 45 minutes with agitation and washed 
with staining buffer for flow cytometry (PBS with 1% goat serum, 1% HI-FBS and 1% 
BSA). Cells then were stained for hMPV F using anti-hMPV polyclonal guinea pig serum 
as primary antibody and Alexa Fluor 568-conjugated goat anti-guinea pig secondary 
antibody. Cells were analyzed on a BD LSRII flow cytometer. Cells stained with primary 
and secondary antibodies without FΔTM were used as controls. 
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Figure 30. Effect of integrin-function blocking antibodies on hMPV and RSV infectivity. 
Data represent three separate experiments, mean % was calculated as percentage of 
fluorescent foci compared to control wells with virus alone in the absence of any 
inhibitor. Means were compared with student’s t test, 2-tailed assuming unequal variance. 
White bars are RSV infected controls, black bars represent hMPV infected cells. 
 
The control LLC-MK2 cells had very low background fluorescence, showing that 
there was little non-specific binding of guinea pig anti-hMPV serum or goat anti-guinea 
pig secondary Ab to LLC-MK2 cells (Figure 31, upper panel). In contrast, cells 
incubated with hMPV FΔTM protein followed by anti-hMPV antibodies showed 
significant increase in fluorescence, indicating FΔTM binding to the cells (Figure 31, 
histogram in the second row). Pre-incubation of LLC cells with function blocking anti-
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αv or anti-β1 antibodies decreased FΔTM binding (Figure 31, two histograms in the 
third row). We also utilized site-directed mutagenesis to produce an RGE-mutant FΔTM 
protein, by changing aspartic acid in the native FΔTM to glutamic acid (RGD to RGE). 
Cells were incubated with the RGE mutant protein then stained similarly to FΔTM 
incubation and staining. We did not detect a significant increase in the fluorescence 
signal, which suggests that RGE mutant protein did not bind to LLC-MK2 cells (Figure 
31, bottom left histogram). These experiments need to be confirmed by replicate assays 
and control experiments with irrelevant proteins (e.g. RSV F) and with other anti-integrin 
antibodies are needed to further confirm the results that we have so far. Nonetheless, 
these data provide strong evidence that hMPV F protein mediates viral binding to cell 
surface integrins. 
siRNA knockdown of αv and β1 integrin expression on LLC-MK2 cells. We used 
an RNAi approach to block integrin gene expression in LLC-MK2 cells. We obtained 
synthetic αV and β1 integrin-specific siRNA oligos (Qiagen) and transfected them into 
LLC-MK2 cells using cationic lipid-mediated transfection. We have optimized this 
protocol and successfully transfected LLC-MK2 cells with siRNA directed against αV 
and β1 integrins, separately and together, and have shown by flow cytometry that cell 
surface expression is decreased (Figure 32). We have also confirmed by quantitative RT-
PCR that amount of αV and β1 integrin mRNAs are decreased (data not shown). These 
cells were then infected with hMPV and infectivity determined using the fluorescent 
focus assay we previously described. Knockdown of αV and β1 integrins substantially 
decreased the infectivity of hMPV in LLC-MK2 cells (Figure 33). 
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 Figure 31. Histograms of flow cytometric analysis of LLC-MK2 cells stained for cell 
surface binding of hMPV F protein. Solid histogram in each panel represents LLC-MK2 
control cells, incubated only with anti-hMPV primary and goat anti-guinea pig, Alexa 
Fluor 568-conjugate secondary antibodies. White histograms show cells incubated with 
FΔTM, anti-αv or anti-β1 antibodies followed by FΔTM and RGE mutant protein, 
respectively, then stained with primary and secondary antibodies against hMPV, as the 
control. Mean fluorescent intensity of events is shown on the y-axis, decades of 
fluorescence are on the x-axis. 
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Figure 32. Flow cytometric analysis of siRNA transfected LLC-MK2 cells. Solid panel 
shows background fluorescence of LLC-MK2 cells stained alone with secondary 
antibody. Wild type LLC cells (first panels in second and third rows) and siRNA-
transfected ones (panels with two histograms) were stained for αv (second row) and β1 
(third row) integrins. Green histograms represent the wild type control for siRNA-
transfected cells. Anti-αv mouse IgG1 and anti-β1 rat IgG were used as primary 
antibodies and goat anti-mouse or goat anti-rat FITC-conjugated antibodies as secondary 
Abs for flow cytometric staining. 
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 Figure 33. Infectivity of LLC-MK2 cells transfected with siRNA for αV and/or β1 
integrins. Mean % infectivity was calculated as percentage of fluorescent foci compared 
to control wells inoculated with virus alone in the absence of any inhibitor. Means were 
compared with student’s t test, 2-tailed assuming unequal variance. Data represent three 
separate experiments. 
 
The greatest inhibition was achieved by transfecting LLC-MK2 cells together 
with both αV and β1 integrin siRNAs. These data confirm that blocking the αV and β1 
integrin interactions with hMPV by inhibiting integrin surface expression significantly 
decreases hMPV infectivity. However, further experiments are necessary to prove that 
hMPV F binding can be also blocked by integrin siRNA-transfection. 
Integrin expression in CHO cells. CHO cells are poorly permissive for hMPV 
infection. They express some α5 and β3 on their surfaces, but lack αv and β1 integrins, 
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which are present in LLC cells and thought to be important in hMPV binding to host cell 
surface based on our previous experimental data. In order to further confirm a specific 
role for αvβ1 integrins in hMPV infection, we performed transient transfection of CHO 
cells with cDNAs encoding either human αv or β1 integrin contained in a mammalian 
expression vector (from Melissa Maginnis in Dr. Dermody’s lab at Vanderbilt 
University). We confirmed successful cDNA transfection and the surface expression of 
integrins on CHO cells by flow cytometry as shown in Figure 34 and the presence of 
integrin mRNA by RT-PCR (data not shown). We also performed the hMPV infection by 
using fluorescent focus assay to detect hMPV infectivity in integrin cDNA-transfected 
CHO cells. Our results showed that expression of either αv or β1 integrin substantially 
increased the permissivity of CHO cells for hMPV (data not shown). Expression of αv 
integrin in CHO cells increased the permissivity by almost 200% (compared to wild type 
CHO-s), and expression of β1 integrin increased the permissivity by over 300%. 
Furthermore, we also proved that this increase in permissivity can be blocked by 
function-blocking anti-integrin antibodies, similarly to the permissivity of LLC-MK2 
cells. Both anti-αV and anti-β1 inhibited hMPV infectivity significantly, and both 
together exhibited additive inhibition (Figure 35). These data strongly suggest that the 
increased permissivity of transfected CHO cells is due to αV and β1 integrins. The next 
experiments planned will use flow cytometry to determine the effect of integrin 
transfection and antibody-mediated blockade on hMPV F protein binding to CHO cells. 
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 Figure 34. Histograms of flow cytometric analysis of integrin surface expression in 
transiently transfected CHO cells. Top panel shows background fluorescence of CHO 
cells stained with secondary antibody alone, as a negative control. Wild type (first panels 
on the left) and transfected (middle and right panels) CHO cells stained for αv (second 
row) or β1 (third row) are shown. Green histograms are the same as wild types, for 
comparison of fluorescent signals in transfected cells. Anti-αv mouse IgG1 and anti-β1 
rat IgG were used as primary antibodies and goat anti-mouse or goat anti-rat FITC-
conjugated antibodies as secondary Abs for flow cytometric staining. 
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 Figure 35. Effect of integrin function-blocking antibodies on infectivity of hMPV in 
integrin-transfected CHO cells. Mean % infectivity was calculated as percentage of 
fluorescent foci compared to control wells inoculated with virus alone in the absence of 
any inhibitor. Means were compared with 2-tailed t test assuming unequal variance. Data 
represent three separate experiments. 
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4.4. Discussion 
Our hypothesis was that cell surface receptors, specifically RGD-binding integrins 
serve as receptor for hMPV and that αvβ1 integrin binding and cell entry is mediated by 
the hMPV fusion protein. The RGD motif is highly conserved in all previously reported 
hMPV F sequences and we also found a correlation between permissivity for hMPV 
infection and surface integrin expression different cell lines. 
We found that LLC-MK2 cells are permissive for hMPV infection and they 
express αvβ1 integrins on the surface along with other RGD-binding receptors. In 
contrast, CHO cells are poorly permissive for hMPV infection and they don’t express 
αvβ1 integrin heterodimers, but the permissivity can be increased by transfecting αv and 
β1 integrin cDNA-s into the cells. We showed that hMPV infectivity could be increased 
by over 300% with integrin expression in CHO cells. Furthermore, we showed that this 
increase could be blocked back with function-blocking anti-integrin antibodies. 
Experiments were performed to prove that the permissivity of LLC-MK2 cells for 
hMPV infection can be inhibited in several ways, and these methods targeted αv and β1 
integrins on the cell surface. We used divalent cation chelator, EDTA, RGD-containing 
linear peptides, and function-blocking anti-integrin antibodies; all of which inhibited 
hMPV infectivity in LLC cells. We also used the technique of RNA interference and 
knocked down αv and β1 integrin mRNA expressions in the cells. These experiments 
further confirmed that hMPV infectivity is related to the presence (or absence) of αv and 
β1 integrins on the cell surface. 
These ‘gain-of-function’ and ‘loss-of-function’ experiments provided starting 
points for further investigations of hMPV F-integrin binding, cell signaling and possible 
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cytoskeletal rearrangement mediated by hMPV F-integrin binding. To prove that hMPV 
F binds to αv and β1 integrins, we will design flow cytometric experiments to monitor 
hMPV F ectodomain binding to siRNA transfected LLC-MK2 cells, and also to integrin 
cDNA-transfected CHO cells. We will use anti-αv and anti-β1 function-blocking 
antibodies, to block binding and irrelevant integrin antibodies to show lack of blockade. 
To confirm RGD-containing F ectodomain binding to integrins, co-purification of hMPV 
F and LLC cell lysate over Histrap column, immunoprecipitation and immunoblots of 
integrins and hMPV F could be performed. 
It has been reported that virus-integrin binding triggers activation of focal 
adhesion kinase (FAK) in infected cells, so we could follow hMPV binding to surface 
receptors by detecting phosphorylation of FAK at the time of virus binding to infected 
cells. Lack of phosphorylation probably would mean no binding to integrins. 
And finally, we could generate RGE-mutant virus in order to directly test the 
infectivity of non-RGD motif F protein mutants in vitro and in vivo in a small animal 
model. It is possible that such a mutant virus will be difficult to recover, if it is less able 
to bind and/or internalize. Future experiments will be necessary to determine which 
specific steps of viral entry are mediated by integrin engagement. Furthermore, it is 
possible that additional cellular receptors for hMPV exist. The results of these 
experiments will advance our understanding of the pathogenesis of a novel emerging 
human virus. The findings will likely have broader implications for the paramyxovirus 
family, which includes a number of important human pathogens. 
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CHAPTER V 
 
ANIMAL MODEL AND VACCINE DEVELOPMENT 
 
5.1. Introduction 
Infectious diseases are responsible for one-fifth of all deaths worldwide, killing at 
least 11 million people per year. Beyond this high death toll millions more children and 
adults suffer disability and illness because they were not immunized. Vaccines are the 
keystones fighting against deadly pathogens. The eradication of smallpox and polio and 
decreasing the global numbers of deaths due to measles all illustrate the benefits of 
vaccination62. Today over 50% of the 10.6 million deaths of young children are due to 
acute respiratory infections, diarrhoeas, malaria, measles and AIDS. HIV pandemic 
affects around 40 million people with more than 14,000 new infections every day. Acute 
respiratory infections (ARIs) are the most important cause of infant and young children 
mortality being responsible nearly 4 million deaths every year mostly in developing 
countries. The main agents causing ARIs include influenza virus, respiratory syncytial 
virus (RSV), parainfluenza virus type 3 (PIV-3), Streptococcus pneumoniae and 
Haemophilus influenzae. Vaccines have been developed against influenza virus, S. 
pneumoniae and H. influenzae, but to date no vaccines are available against RSV, hPIV-
3, metapneumovirus (hMPV) or the new coronavirus strains63. 
Several approaches have been used to develop effective vaccines against 
respiratory viruses. In case of influenza virus the currently available vaccines are the 
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inactivated vaccines made from inactivated, detergent-split influenza virus grown in the 
allantoic cavity of embrionated chicken eggs. Another approach to influenza vaccines has 
been the live-attenuated vaccines by using cold-adapted (ca) virus strains. The ca strains 
grow well in chicken eggs at 25-33°C and have reduced replication titer at 37°C. Subunit, 
synthetic peptide and DNA vaccines are also under development for influenza. Subunit 
vaccines use recombinant HA protein64 produced in serum-free cultures with baculovirus 
expression systems. Synthetic peptides for nasal administration showed protective 
efficacy in mice and clinical trials are planned. An epidermal DNA vaccine was found to 
be safe and immunogenic in subjects with prevaccinnation antibodies to influenza, other 
DNA vaccines are at the early stage of development. 
Several strategies have recently been used for RSV vaccine development, 
including generation of peptide, subunit and live attenuated vaccines. Of these, only 
inactivated, subunit and live attenuated RSV vaccines have been evaluated in clinical 
trials. Early studies in the 1960s showed that children vaccinated with formalin-
inactivated RSV vaccines suffered from more severe disease on subsequent exposure to 
virus as compared to the unvaccinated control group. These early studies resulted 
hospitalization of the 80% of vaccinees and two deaths. The enhanced severity of disease 
was reproducible in animal models and it was thought to result from lack of local 
immunity, inadequate serum neutralizing antibody level and an elevated type 2 helper T-
cell-like (Th2) immune response. Purified fusion protein (PFP) subunit vaccines for RSV 
have been shown to be immunogenic and safe in seropositive children and adults. 
However, in rodent studies, Th2-type responses have been observed following 
inoculation with purified F protein, leading to concern that this could occur in 
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seronegative infants and produce enhanced disease with natural infection. An immature 
or non-native conformation of F protein in these preparations may account for the 
phenomenon of immune-mediated enhanced disease. 
Human metapneumovirus shares substantial homology with RSV and its 
glycoproteins. To develop a vaccine against hMPV many issues of the RSV vaccine 
development studies need to be considered. Previously, Williams et al. showed that 
cotton rat is a good animal model for hMPV infection and protective immunity38 and 
anti-hMPV polyclonal serum was produced in our laboratory by vaccination of guinea 
pigs with DNA-F construct (pcDNA3.1+-F). We wanted to test the hypothesis that F 
protein is a major protective antigen for hMPV and it is immunogenic in cotton rats. We 
immunized cotton rats twice, at two-week interval (0 and 14 days) with either control 
vector (pcDNA3.1), DNA-F alone, DNA-F followed by FΔTM protein, or FΔTM protein 
alone. Animals were bled on day 27 to measure serum antibodies to hMPV. All groups 
were challenged intranasally on day 28 with live hMPV. Four days post-infection, the 
animals were sacrificed and nasal and lung tissue titers for virus were measured by 
plaque assay. Lung tissue sections from animals were also examined by a pathologist and 
scored in a group-blinded fashion. 
 
5.2. Materials and Methods 
Immunization of animals. Animals were purchased at 5-6 weeks of age from a 
commercial breeder (Harlan, Indianapolis, IN), fed standard diet and water ad libitum and 
kept in microisolator cages. Animals were anesthetized by methoxyflurane (Metofane) 
inhalation prior to immunization, blood sampling or virus inoculation. In initial 
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experiments, guinea pigs were immunized at monthly intervals with 100 µg of DNA-F 
intramuscularly (i.m.) and 10 µg of DNA-F intradermally. Cotton rats immunized with 
DNA received 100 µg i.m. of either control vector pcDNA3.1 or pcDNA3.1-F (DNA-F). 
Protein immunizations consisted of 25 µg FΔTM adjuvanted with TiterMax Gold 
(Sigma). Serum was collected from cotton rats by retro-orbital bleed. Serum hMPV-
neutralizing titers were determined by a plaque reduction assay. 
hMPV challenge. The virus strain used was hMPV strain TN/96-12, a genotype 
group A1 virus, according the proposed nomenclature. Virus was grown in LLC-MK2 
cells and purified over a 20%/60% discontinuous sucrose gradient. This virus stock was 
determined to have a titer of 1 x 106 plaque-forming units (pfu)/ml by plaque titration in 
LLC-MK2 cell monolayer cultures. Cotton rats were inoculated on day 28 intranasally 
with 1 x 105 pfu in a volume of 100 µl. Four days later, the animals were sacrificed by 
CO2 asphyxiation, and exsanguinated. Nasal and right lung tissues were harvested and 
immediately homogenized, while the left lungs were inflation-fixed with 4% 
paraformaldehyde. The right lungs were pulverized in ice-cold glass homogenizers and 
nasal turbinates were ground with sterile sand in a cold porcelain mortar and pestle in 3 
ml of ice-cold Hanks’ balanced salt solution. Tissue homogenates were centrifuged at 4 
ºC for 10 minutes at 300 x g and the supernatants were collected, and snap-frozen in 
liquid nitrogen. Virus yields were measured by plaque titration. Comparisons between 
groups were made using a 2-tailed Student’s t test that assumed unequal variance. The 
Vanderbilt Institutional Animal Care and Use Committee approved the study. 
Pathological examination. Specimens for histological examination were 
embedded in paraffin, processed and slides prepared in the Vanderbilt 
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Immunohistochemistry Core. All lobes of the right lung were examined, including 2 
sections per lung. Sections were reviewed by a pathologist experienced in small animal 
studies of RSV and hMPV without knowledge of the immunization status of the 
specimens. Slides were examined in their entirety in a group-blinded fashion. The 
following compartments of the lung were assessed: alveolar spaces, airways at all levels, 
interstitium, and vessels (both arteries and veins). Inflammatory infiltrates were evaluated 
for location, severity, and composition (cell types: small mononuclear cells, transformed 
lymphocytes, histiocytes, neutrophils, eosinophils). The perivascular ‘cuff thickness’ was 
assessed semiquantitatively as a measure of severity of inflammation and was evaluated 
at the point of minimal diameter of the structure. The degrees of inflammation were 
graded as follows: 0 = no infiltrate; 1+ = most vessels had an infiltrate up to 4 cells thick; 
2+ = most vessels had an infiltrate 5–7 cells thick; 3+ = most vessels had an infiltrate 
greater than 7 cells thick. Interstitial alveolar cellularity was graded as follows: 0 = no 
infiltrate; 1+ = minimal increased cellularity without widening of septa; 2+ = obvious 
increased cellularity with widening of septa; and 3+ = markedly increased cellularity with 
thickened septa; this score also included blood or edema fluid in the tissue space. Lung 
sections were also stained with Periodic Acid-Schiff (PAS) to quantitate mucus. 
 
5.3. Results 
We immunized cotton rats intramuscularly twice, at 2-week intervals, with 
pcDNA3.1 alone (vector control), DNA-F, FΔTM protein adjuvanted with TiterMax 
Gold (Sigma), or DNA-F followed by FΔTM (Table 3.). Animals were bled on day 27 
for measurement of serum antibodies to hMPV. All groups except the vector control 
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group had elevated immunofluorescent antibody titers to hMPV-infected LLC-MK2 cells 
(range 1:320 to 1:1280) (Figure 36 C). 
Animals were challenged with hMPV virus on day 28 and sacrificed four days 
post-infection. Animals immunized twice with FΔTM showed a modest, but highly 
significant level of protection against shedding in nasal tissues compared to control 
animals (mean 2.5 × 103 pfu/g vs. 5.3 × 104 pfu/g, p=0.008, Figure 36 A), while DNA-
F/FΔTM and DNA-F/DNA-F groups showed reductions in nasal virus shedding that did 
not reach significance (mean 2.2 × 104 pfu/g and 3 × 104 pfu/g, respectively, Figure 36 
A). Conversely, 2 doses of FΔTM protein alone were highly protective against lung virus 
shedding, giving a >1,500-fold reduction in mean lung hMPV titer compared to controls 
(mean 1.9 × 101 pfu/g vs. 2.9 × 104 pfu/g, p=0.02, Figure 36 B). DNA-F/FΔTM and 
DNA-F/DNA-F groups showed modest but highly significant reduction of virus 
replication in the lungs (mean 2.2 × 103 pfu/g and 7 × 102 pfu/g, respectively, Figure 36 
B). Cotton rats immunized with the vector control exhibited nasal and lung tissue virus 
replication similar to naïve cotton rats during primary hMPV infection, as described by 
Williams et al.38. 
We measured in vitro serum neutralizing titers in all groups prior to challenge. 
The FΔTM/ FΔTM immunized animals developed a significant rise in hMPV-
neutralizing titers (mean 1:570, range 1:250-1:984, Figure 36 C). This titer was 
markedly higher than the mean serum neutralizing titer of 1:180 we previously observed 
in cotton rats following primary infection with hMPV38. The DNA-F/DNA-F group 
exhibited a rise in serum neutralizing titer that approached significance (mean 1:132, 
range 1:33 to 1:250, Figure 36 C), while only one animal in the DNA-F/FΔTM group 
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showed a significant neutralizing antibody titer (mean 1:86, range 1:10 to 1:282, Figure 
36 C), despite this group exhibiting a significant reduction in lung virus shedding (Figure 
36 B). 
Lung sections from the animals were studied by a pathologist in a group blinded 
fashion. There were no major differences in pathological changes seen in the lungs of any 
groups. However, subtle differences between groups were noted in Table 3. The animals 
that were immunized with vector control had mild (1+) mononuclear cell interstitial 
infiltrates, with pronounced (1-2+) peri-bronchiolar lymphocytic cuffing (Figure 37). 
This is similar to changes in cotton rats with primary hMPV infection previously 
described by Williams et al.38. All animals in the vector control group had copious (3+) 
mucous plugs present in the large airways (Figure 37 E). Animals immunized with 
DNA-F/FΔTM exhibited mild to moderate (1-2+) interstitial and circumferential peri-
bronchiolar mononuclear cell infiltrates (Figure 37 B), with mucous plugs present in 
only 1 of 4 animals. Lungs from cotton rats immunized with DNA-F/DNA-F exhibited 
mild to moderate (1-2+) interstitial infiltrates with thickening of the interstitium, and 
moderate (2+) circumferential peri-bronchiolar lymphoid cuffs (Figure 37 C). Animals 
immunized with FΔTM/FΔTM showed mild (1+) interstitial mononuclear infiltrates and 
an absence of peri-bronchiolar mononuclear cuffs (Figure 37 D). Mild (1+) airway 
mucus was detected in 2 of 4 animals (Figure 37 F). 
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 Figure 36. Nasal (A) and lung (B) hMPV titer and reciprocal serum antibody titer (C) in 
cotton rats. See explanation in the text above. 
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Table 3. Histopathological scoring of lung sections from immunized groups of cotton 
rats after hMPV challenge. Lung sections were examined in a group-blinded fashion. 
Scoring ranged from 0 (absent) to 3+ (severe), as described in text. 
 pcDNA3.1/pcDNA3.1 DNA-F/FΔTM DNA-F/DNA-F FΔTM/ FΔTM 
Interstitial 
infiltrates 
1+ 1-2+ 1-2+ 1+ 
Peri-bronchiolar 
infiltrates 
1-2+ 1+ 2+ 0 
PAS+ 
(mucus plugs) 
3+ 
(all animals) 
1+ 
(1 of 4) 
0 1+ 
(2 of 4) 
 
 
5.4. Discussion 
Our results indicate that both DNA-F and FΔTM, alone or in combination, were 
immunogenic in cotton rats and induced partial protection against virus shedding. Virus 
titer results in the nasal turbinates showed that animals immunized with FΔTM twice had 
>20-fold reduction in nasal virus titer, while the DNA-F/DNA-F and DNA-F/FΔTM 
groups had modest decrease in the nasal virus titer after hMPV challenge. In the lungs, 
however, we found more significant reductions of viral titers. The highest protection in 
the lower respiratory tract was detected in animals immunized twice with FΔTM protein, 
with a >1,500-fold reduction in the lung virus titer. DNA-F/DNA-F and DNA-F/FΔTM 
immunized animals also exhibited significant virus titer reductions in the lung compared 
to the control group, which was immunized with vector alone. 
The serum neutralizing antibody titer results showed that all three groups 
(FΔTM/FΔTM, DNA-F/DNA-F and DNA-F/FΔTM) had hMPV-specific antibody 
response after two vaccinations. The highest antibody titer (mean: 1:570) was detected in 
the FΔTM/FΔTM group correlating with the greater degree of protection in the lungs. 
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DNA-F/DNA-F and DNA-F/FΔTM groups had less robust neutralizing titer, as they 
showed less protection against virus shedding in the nose and lung. 
Pathological examination of the lung tissues can give information about enhanced 
lung histopathology following virus challenge. As it was observed in case of the 
formalin-inactivated RSV vaccine, upon challenge enhanced disease and Th2 type 
immune response occurred in children, who were vaccinated. In our vaccination study the 
highest histopathological scores were observed in the vector control group. In fact, 
animals that were immunized with FΔTM/FΔTM had the lowest scores in peri-
bronchiolar infiltrates, which likely reflects decreased viral replication due to the high 
serum neutralizing antibody titer. 
These data all suggest that our purified FΔTM protein construct offers potential as 
a subunit vaccine, as we demonstrated that DNA-F and FΔTM, alone or in combination, 
are immunogenic and induce protective immune response in cotton rats. Although further 
studies are necessary to prove that no enhance disease and type 2 helper T-cell response 
occurs following FΔTM vaccination, these findings have important implications in 
hMPV vaccine and prophylactic antibody development. 
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 Figure 37. Representative sections demonstrating histopathology of hMPV infection in 
lungs of immunized cotton rats. A. Lung of control vector immunized 
(pcDNA3.1/pcDNA3.1) animal exhibits mild to moderate interstitial and significant peri-
bronchiolar infiltrates (arrow). B. Lung section of DNA-F/FΔTM immunized animal 
exhibits moderate interstitial and moderate peri-bronchiolar mononuclear infiltrates 
(arrow). C. The lung of DNA-F/DNA-F immunized cotton rats exhibit moderate 
interstitial and mild peri-bronchiolar infiltrates (arrow). D. Lung section of FΔTM/FΔTM 
immunized cotton rat exhibits minimal interstitial mononuclear infiltrates, no peri-
bronchiolar infiltrates, no alveolitis (arrows). E. Periodic acid-Schiff (PAS) staining 
reveals copious mucus in the large airways of control vector immunized animals. F. PAS 
staining of FΔTM/FΔTM immunized cotton rat lung shows minimal mucus in airway 
lumen (arrow). A-D, H&E staining. All sections original magnification x25. 
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CHAPTER VI 
 
CONCLUSION 
 
HMPV is a recently discovered Paramyxovirus, which causes serious upper and 
lower respiratory tract infections in infants, young children, elderly and 
immunocompromized people. Based on sequence homology with other paramyxoviruses, 
hMPV F gene encodes for the fusion protein, which mediates virus-cell membrane fusion 
and it is thought to form characteristic hexameric coiled coil conformation in its fusion 
active state. 
To confirm that F protein has a hexameric α-helical structure, we generated a 
sequence-optimized clone of the hMPV F gene and modified it by removing the 
transmembrane domain- and cytoplasmic tail-encoding regions. The gene has been 
cloned into pcDNA3.1/myc-His mammalian expression vector, which has been 
transfected into 293-F suspension adapted cell line. We successfully expressed and 
affinity purified the soluble hMPV F ectodomain with C-terminal c-myc-epitope and 
6xHistidine tag, and this recombinant protein served as subject for further structural, 
biochemical and immunogenic characterizations. 
The native F ectodomain formed trimers, which fell apart into stable monomers 
under denaturing conditions. Our results showed that the protein has a dominant α-helical 
secondary structure, probably due to the hexameric HR-1/HR-2 fusion core formation in 
the F1 subunit, although it is not known whether this represents the pre-fusion, the post-
fusion or the pre-hairpin intermediate state. The expressed protein underwent post-
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translational modifications, and it is N-glycosylated at all three N-glycosylation sites. 
Glycosylation of the F1 subunit is important and necessary in proper protein folding and 
transport, since mutations at the F1 glycosylation sites affected expression of the mutated 
proteins. Our disulfide-mapping studies indicated that all fourteen cysteines in hMPV F 
participate in disulfide-bond formations, which have important role in stabilizing the 
structure of the protein. 
Our hMPV FΔTM construct can be recognized by anti-hMPV polyclonal human 
and guinea pig sera and also by monoclonal antibodies generated against hMPV. Surface 
plasmon resonance studies showed that this antibody-antigen interaction is a strong, 
specific binding. These results suggest that the expressed ectodomain retains native 
conformation and presents some antigenic epitopes on its surface that are important in 
antigen recognition. 
A subset of integrin receptors binds to the specific RGD recognition sequence and 
this motif can be found in all of the reported hMPV F sequences. A number of human 
viruses utilize RGD-recognizing integrins as receptors or co-receptors and our most 
recent data suggest that RGD-binding integrins serve as receptors for hMPV too. 
We also tested the hypothesis that F is a major protective antigen for hMPV. We 
immunized cotton rats with the purified F ectodomain and found that it induced robust 
neutralizing antibody responses and protected animals against virus shedding in the lungs 
following wild-type virus challenge. Our findings indicate that F∆TM retains several 
important characteristics of native hMPV F protein, suggesting that it is a promising 
vaccine candidate and a valuable reagent for functional and structural studies of this 
important hMPV protein. 
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Future work 
The future studies of hMPV F protein will probably concentrate on two major 
fields: 1) biochemical and structural characterizations and crystallization of the protein 
and 2) immunogenic studies with antibody and vaccine development strategies. 
The ultimate goal in structural studies is to generate stable crystals of the properly 
folded, native protein and determine its crystal structure. However, only three 
paramyxovirus F protein crystal structures28, 34, 35 are known to date, and all of them are 
from modified polypeptides, not from the actual native fusion protein. Solving the atomic 
structure of a native paramyxovirus F protein in its pre-and post-fusion and metastable 
state will be a major achievement and give us information to understand the structural 
and biochemical bases of viral entry, fusion and pathogenesis. 
Data from structural and biochemical experiments will also help the immunogenic 
studies and vaccine development. Acute respiratory infections are the most important 
cause of infant and young children mortality being responsible nearly 4 million deaths 
every year, and to date there is no effective vaccine available. In order to develop novel 
vaccines, either based on protein antigens or prophylactic monoclonal antibodies, it is 
necessary to know the biochemical properties and structural details of the targeted 
antigen or the antigenic binding site of the antibody, so for this reason hMPV vaccine 
development will utilize the structural information on hMPV fusion protein. 
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APPENDIX A 
 
FPLC PURIFICATION OF HMPV F ECTODOMAIN USING HISTRAP COLUMN 
AND ÄKTA-FPLC SYSTEM 
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Table 4. Parameters for purification protocol of hMPV F ectodomain using ÄKTA-FPLC 
system and 5 ml HisTrap column. 
Block Variable Value Range 
    
Main Column HisTrap_5_ml  
Start_with_PumpWash Wash_InletA ON  
 Wash_InletB Off  
Flow_Rate Flow_Rate {ml/min} 5 0.00 - 20.00 
Column_Pressure_Limit Column_PressureLimit {MPa} 0.3 0.000 - 5.000 
Averaging_Time_UV Averaging_Time_UV 5.1  
Alarm_Sample_PressureLimit Sample_PressureLimit {MPa} 0.3 0.00 - 2.00 
Eluent_A_Inlet Eluent_A_Inlet A1  
Start_Conc_B Start_ConcB {%B} 0 0.0 - 100.0 
Column_Equilibration Equilibrate_with {CV} 5 0.00 - 999999.00 
Aut_PressureFlow_Regulation System_Pump PressFlowControl  
 System_PressLevel {MPa} 3 0.000 - 5.000 
 System_MinFlow {ml/min} 0.1 0.000 - 20.000 
Direct_Sample_Loading Injection_Flowrate {ml/min} 5 0.0 - 50.0 
 Volume_of_Sample {ml} 600 0.0 - 20000.0 
PressureReg_Sample_Pump Sample_Pump Normal  
 Sample_Min_Flow {ml/min} 0.1 0.1 - 49.9 
Wash_Out_Unbound_Sample Wash_column_with {CV} 2 0.00 - 999999.00 
Buffer_Inlet_A_Segment_1 1_Buffer_Inlet_A A1  
ConcB_Step_1 1_ConcB_Step {%B} 6 0.0 - 100.0 
Wash_1 1_Wash_Inlet_A OFF  
 1_Wash_Inlet_B OFF  
Fractionation_Segment_1 1_Tube_Type 18mm  
 1_Fraction_Size {ml} 11 
0.000 - 
99999.000 
 1_Start_at FirstTube  
 1_PeakFrac_TubeType 18mm  
 1_PeakFraction_Size {ml} 0 
0.000 - 
99999.000 
 1_PeakFrac_Start_at NextTube  
Step_1 1_Length_of_Step {CV} 4 0.00 - 999999.00 
Buffer_Inlet_A_Segment_2 2_Buffer_Inlet_A A1  
ConcB_Step_2 2_ConcB_Step {%B} 25 0.0 - 100.0 
Wash_2 2_Wash_Inlet_A OFF  
 2_Wash_Inlet_B OFF  
Fractionation_Segment_2 2_Tube_Type 18mm  
 2_Fraction_Size {ml} 11 
0.000 - 
99999.000 
 2_Start_at NextTube  
 2_PeakFrac_TubeType 18mm  
 2_PeakFraction_Size {ml} 0 
0.000 - 
99999.000 
 2_PeakFrac_Start_at NextTube  
Step_2 2_Length_of_Step {CV} 4 0.00 - 999999.00 
Gradient_Delay Gradient_Delay {ml} 10 0.00 - 999999.00 
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SPR-BIACORE ANALYSIS OF HMPV F BINDING TO HMPV-SPECIFIC HUMAN 
MONOCLONAL ANTIBODY 
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Figure 38. Kinetic analysis of hMPV F binding to anti-HMPV human monoclonal Fab. 
Binding curves (colored) for different Fab concentrations are fitted with a 1:1 Langmuir 
binding model (black curves). 
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